BLOOD CANCER UNITED INC: Form 990, tax year 2011
View the entire original 990 at ProPublica ↗
- Organization
- BLOOD CANCER UNITED INC (EIN 13-5644916)
- Tax period
- 2011-07-01 to 2012-06-30
- Filed
- 2013-02-15
- IRS object ID
- 201300469349302085
- Schema version
- 2011v1.5
- Source
- Download XML · Original 990 at ProPublica
Every field in the e-filed return. Faint text is the IRS element name, for citing.
- Return header
- Form 990
- Schedule A
- Schedule B
- Schedule C
- Schedule D
- Schedule F
- Schedule G
- Schedule I
- Schedule J
- Schedule M
- Schedule O
- Schedule R
Return header ReturnHeader
| Field | Value | IRS element (for citing) |
|---|---|---|
| Timestamp | 2013-02-15T14:28:39-06:00 | Timestamp |
| Tax Period End Date | 2012-06-30 | TaxPeriodEndDate |
Preparer Firm PreparerFirm
Preparer Firm Business Name PreparerFirmBusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | KPMG LLP | BusinessNameLine1 |
Preparer Firm US Address PreparerFirmUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 345 PARK AVENUE | AddressLine1 |
| City | NEW YORK | City |
| State | NY | State |
| ZIP Code | 101540102 | ZIPCode |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return Type | 990 | ReturnType |
| Tax Period Begin Date | 2011-07-01 | TaxPeriodBeginDate |
Filer Filer
| Field | Value | IRS element (for citing) |
|---|---|---|
| EIN | 135644916 | EIN |
Name Name
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | THE LEUKEMIA & LYMPHOMA SOCIETYINC | BusinessNameLine1 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Name Control | LEUK | NameControl |
| Phone | 9149495213 | Phone |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 1311 MAMARONECK AVENUE | AddressLine1 |
| Address Line2 | ROOM/SUITE 310 | AddressLine2 |
| City | WHITE PLAINS | City |
| State | NY | State |
| ZIP Code | 10605 | ZIPCode |
Officer Officer
| Field | Value | IRS element (for citing) |
|---|---|---|
| Name | JAMES T NANGLE | Name |
| Title | SR VICE PRESIDENT & CFO | Title |
| Phone | 9149495213 | Phone |
| Date Signed | 2013-02-13 | DateSigned |
| Authorize Third Party | true | AuthorizeThirdParty |
Preparer Preparer
| Field | Value | IRS element (for citing) |
|---|---|---|
| Name | KPMG LLP | Name |
| Phone | 2127589700 | Phone |
| Date Prepared | 2013-02-13 | DatePrepared |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Tax Year | 2011 | TaxYear |
| Build TS | 2016-03-07 17:11:31Z | BuildTS |
Form 990 IRS990
| Field | Value | IRS element (for citing) |
|---|---|---|
| Name Of Principal Officer Person | JOHN WALTER PRESIDENT CEO | NameOfPrincipalOfficerPerson |
Address Principal Officer US AddressPrincipalOfficerUS
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 1311 MAMARONECK AVENUE | AddressLine1 |
| City | WHITE PLAINS | City |
| State | NY | State |
| ZIP Code | 10605 | ZIPCode |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Gross Receipts | 416500338 | GrossReceipts |
| Group Return For Affiliates | false | GroupReturnForAffiliates |
| Organization501c3 | X | Organization501c3 |
| Web Site | WWW.LLS.ORG | WebSite |
| Type Of Organization Corporation | X | TypeOfOrganizationCorporation |
| Year Formation | 1949 | YearFormation |
| State Legal Domicile | NY | StateLegalDomicile |
| Activity Or Mission Description | OUR MISSION IS TO CURE LEUKEMIA, LYMPHOMA, HODGKIN'S DISEASE AND MYELOMA, AND IMPROVE THE QUALITY OF LIFE OF OUR PATIENTS AND THEIR FAMILIES. | ActivityOrMissionDescription |
| Nbr Voting Members Governing Body | 26 | NbrVotingMembersGoverningBody |
| Nbr Independent Voting Members | 26 | NbrIndependentVotingMembers |
| Total Nbr Employees | 1942 | TotalNbrEmployees |
| Total Nbr Volunteers | 3000000 | TotalNbrVolunteers |
| Total Gross UBI | 0 | TotalGrossUBI |
| Contributions Grants Prior Year | 270364921 | ContributionsGrantsPriorYear |
| Contributions Grants Current Year | 282672073 | ContributionsGrantsCurrentYear |
| Program Service Revenue CY | 0 | ProgramServiceRevenueCY |
| Investment Income Prior Year | 10990644 | InvestmentIncomePriorYear |
| Investment Income Current Year | 8039879 | InvestmentIncomeCurrentYear |
| Other Revenue Prior Year | 2476936 | OtherRevenuePriorYear |
| Other Revenue Current Year | 2111041 | OtherRevenueCurrentYear |
| Total Revenue Prior Year | 283832501 | TotalRevenuePriorYear |
| Total Revenue Current Year | 292822993 | TotalRevenueCurrentYear |
| Grants And Similar Amnts Prior Year | 109608494 | GrantsAndSimilarAmntsPriorYear |
| Grants And Similar Amnts CY | 115731627 | GrantsAndSimilarAmntsCY |
| Benefits Paid To Members CY | 0 | BenefitsPaidToMembersCY |
| Salaries Etc Prior Year | 83658857 | SalariesEtcPriorYear |
| Salaries Etc Current Year | 86776477 | SalariesEtcCurrentYear |
| Total Prof Fundrsng Exp Prior Year | 9810826 | TotalProfFundrsngExpPriorYear |
| Total Prof Fundrsng Exp CY | 10175403 | TotalProfFundrsngExpCY |
| Total Fundrsng Exp Current Year | 47258877 | TotalFundrsngExpCurrentYear |
| Other Expense Prior Year | 77762947 | OtherExpensePriorYear |
| Other Expenses Current Year | 79711007 | OtherExpensesCurrentYear |
| Total Expenses Prior Year | 280841124 | TotalExpensesPriorYear |
| Total Expenses Current Year | 292394514 | TotalExpensesCurrentYear |
| Revenues Less Expenses Prior Year | 2991377 | RevenuesLessExpensesPriorYear |
| Revenues Less Expenses CY | 428479 | RevenuesLessExpensesCY |
| Total Assets BOY | 224271874 | TotalAssetsBOY |
| Total Assets EOY | 223445924 | TotalAssetsEOY |
| Total Liabilities BOY | 104487981 | TotalLiabilitiesBOY |
| Total Liabilities EOY | 109397145 | TotalLiabilitiesEOY |
| Net Assets Or Fund Balances BOY | 119783893 | NetAssetsOrFundBalancesBOY |
| Net Assets Or Fund Balances EOY | 114048779 | NetAssetsOrFundBalancesEOY |
| Info In Schedule O Part III | X | InfoInScheduleOPartIII |
| Mission Description | OUR MISSION IS TO CURE LEUKEMIA, LYMPHOMA, HODGKIN'S DISEASE AND MYELOMA, AND IMPROVE THE QUALITY OF LIFE OF OUR PATIENTS AND THEIR FAMILIES. | MissionDescription |
| Significant New Program Services | false | SignificantNewProgramServices |
| Significant Change | false | SignificantChange |
| Expense | 70324176 | Expense |
| Grants | 66713099 | Grants |
| Description | A) RESEARCH PROGRAMS: WITH ADVISORY INPUT FROM RECOGNIZED BIOMEDICAL RESEARCH EXPERTS, LLS FUNDS EXEMPLARY PROJECTS ACROSS THE ENTIRE RESEARCH CONTINUUM RELEVANT TO IMPROVED OUTCOMES FOR BLOOD CANCER PATIENTS, FROM BASIC LABORATORY SCIENCE THROUGH CLINICAL TRIALS, AND FROM INVESTIGATOR-INITIATED RESEARCH TO PRIVATE-SECTOR DRUG DEVELOPMENT ALLIANCES. LLS IS DELIBERATE AND PURPOSEFUL IN FINDING AND SUPPORTING RESEARCH THAT IS MOST LIKELY TO HELP PATIENTS AS SOON AS POSSIBLE. (CONTINUED ON SCHEDULE O) TO DATE, LLS HAS INVESTED MORE THAN 875 MILLION IN RESEARCH AIMED AT HELPING ALL BLOOD CANCER PATIENTS LIVE BETTER, LONGER LIVES. WE WILL CONTINUE TO SUPPORT RESEARCH THROUGH OUR INNOVATIVE AND INTEGRATED FUNDING PROGRAMS, UNTIL EVERY PATIENT HAS A SAFE AND EFFECTIVE THERAPY. IN FISCAL YEAR 2012, LLS SUPPORTED RESEARCH IN THE U.S., CANADA AND 7 OTHER COUNTRIES WITH A TOTAL RESEARCH DISBURSEMENT OF APPROXIMATELY 66 MILLION. RESEARCH FUNDING WAS DISTRIBUTED ACROSS ALL BLOOD CANCERS. OUR CRITICAL ROLE LLS PROGRAMS ACCELERATE RELEVANT RESEARCH OUTCOMES BY: - BUILDING A FOCUSED RESEARCH WORK-FORCE: ASSURING THE NEXT ROUND OF BREAKTHROUGHS REQUIRES THAT YOUNG INVESTIGATORS BE ENCOURAGED TO WORK IN BLOOD CANCER RESEARCH FIELDS. - TURNING DISCOVERIES INTO NEW THERAPIES: FUNDAMENTAL NEW FINDINGS CAN BE TRANSLATED INTO SAFE AND EFFECTIVE TREATMENTS THAT CAN ULTIMATELY PROLONG AND ENHANCE PATIENT LIVES. - SUPPORTING SYNERGY: LARGE GRANTS AND CONTRACTS ENABLE SCIENTISTS IN ACADEMIA AND THE PRIVATE-SECTOR TO COLLABORATE, COMBINING RESOURCES AND EXPERTISE TO PRODUCE MORE AND FASTER ADVANCES. - FILLING A VOID: RESEARCH PROJECTS THAT ARE HIGH-RISK AND/OR ADDRESS RARE CANCERS ARE LESS LIKELY TO BE FUNDED BY GOVERNMENT AGENCIES OR FOR-PROFIT COMPANIES, BUT MAY PROVIDE IMPORTANT ADVANCES. - SPEEDING NEW TREATMENTS TO PATIENTS: PARTNERING WITH BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES CAN ADVANCE PROMISING THERAPIES THROUGH CLINICAL TESTING, FASTER. PAST ADVANCES MADE WITH LLS RESEARCH FUNDING GENEROUS DONORS HAVE HELPED LLS SUPPORT RESEARCH THAT HAS ALREADY BENEFITED BLOOD CANCER PATIENTS AND MANY OTHERS. ADVANCES INCLUDE: - MULTI-DRUG THERAPIES THAT ARE MORE EFFECTIVE THAN TREATMENTS WITH SINGLE ANTI-CANCER AGENTS, - BONE MARROW / STEM CELL TRANSPLANTATION AND SUPPORTIVE CARE TREATMENTS FOR PATIENTS WHO RELAPSE DESPITE THE BEST AVAILABLE THERAPY, - TESTS THAT DISTINGUISH SPECIFIC CHARACTERISTICS OF PARTICULAR BLOOD CANCERS FOR ACCURATE DIAGNOSIS OF CANCER SUBTYPES, AND FOR "RISK STRATIFICATION" TO SELECT AN OPTIMAL THERAPY. TARGETED THERAPY RESEARCH DISCOVERING THE MOLECULAR ABNORMALITIES THAT CAUSE PARTICULAR TYPES OF BLOOD CANCER HAS BEEN USEFUL IN DIAGNOSIS AND RISK STRATIFICATION, AND IN NEW "TARGETED DRUG" DEVELOPMENT. LLS-FUNDED INVESTIGATORS HAVE HELPED ADVANCE MOLECULARLY TARGETED TREATMENTS THAT CAN SELECTIVELY KILL BLOOD CANCER CELLS VERSUS NORMAL CELLS. MANY OF THESE NEW TREATMENTS BENEFIT NOT ONLY BLOOD CANCER PATIENTS, BUT ALSO PATIENTS WITH OTHER DISEASES. FOR EXAMPLE: - GLEEVEC IS FDA-APPROVED FOR PATIENTS OF ALL AGES WITH CHRONIC MYELOID LEUKEMIA (CML), AND IS ALSO APPROVED FOR PATIENTS WITH ONE FORM OF ACUTE LYMPHOID LEUKEMIA (ALL), MYELODYSPLASTIC SYNDROMES (MDS), MYELOPROLIFERATIVE DISORDERS AND RARE FORMS OF STOMACH AND SKIN CANCERS. RELATED DRUGS, SPRYCEL AND TASIGNA, ARE APPROVED FOR PATIENTS WHO DO NOT BENEFIT FROM GLEEVEC. ONE OR MORE OF THESE DRUGS ARE ALSO SHOWING PROMISE FOR PATIENTS WITH VARIOUS LYMPHOMAS, ACUTE MYELOID LEUKEMIA (AML), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), AND OTHER CANCERS, INCLUDING BRAIN, BREAST, HEAD-AND-NECK, LUNG, PANCREATIC, AND PROSTATE CANCERS, AND PATIENTS WITH OTHER DISEASES INCLUDING ALZHEIMER'S, ASTHMA AND PULMONARY HYPERTENSION. - RITUXAN WAS THE FIRST FDA-APPROVED, ANTI-CANCER ANTIBODY DRUG, DEVELOPED FOR PATIENTS WITH FORMS OF B-CELL NON-HODGKIN LYMPHOMA (NHL). IT IS NOW ALSO APPROVED FOR CLL PATIENTS AND AS A "MAINTENANCE" THERAPY FOR FOLLICULAR LYMPHOMA PATIENTS, AND SHOWING PROMISE FOR PATIENTS WITH ALL AND AFTER STEM CELL TRANSPLANTATION. IN ADDITION, IT IS APPROVED FOR TREATING PATIENTS WITH SEVERE RHEUMATOID ARTHRITIS AND TWO OTHER TYPES OF AUTOIMMUNE DISEASES. A RELATED ANTIBODY DRUG, ARZERRA, IS APPROVED FOR CLL PATIENTS AND SHOWING WIDER PROMISE. - VELCADE, THALIDOMID AND REVLIMID ARE FDA-APPROVED FOR PATIENTS WITH MYELOMA AND ARE ALSO HELPING SOME PATIENTS WITH HODGKIN LYMPHOMA AND NHL. KRYPOLIS WAS RECENTLY APPROVED FOR MYELOMA PATIENTS FOR WHOM AT LEAST TWO PRIOR THERAPIES WERE INSUFFICIENT. ONE OR MORE OF THESE DRUGS ARE NOW BEING TESTED FOR PATIENTS WITH T-CELL AND B-CELL FORMS OF LYMPHOMA, ACUTE LEUKEMIAS, AS WELL AS AIDS-RELATED KAPOSI SARCOMA AND BRAIN, BREAST, COLORECTAL, HEAD-AND-NECK, KIDNEY, LIVER, LUNG, OVARIAN AND PROSTATE CANCERS, AND ALZHEIMER'S DISEASE. - ISTODAX, ZOLINZA, DACOGEN AND VIDAZA TARGET SMALL CHEMICAL, "EPIGENETIC" CHANGES. THE FIRST TWO DRUGS ARE APPROVED FOR PATIENTS WITH PERIPHERAL T-CELL LYMPHOMAS; THE LATTER DRUGS ARE APPROVED FOR MDS PATIENTS. ONE OR MORE OF THESE DRUGS ARE BEING TESTED FOR PATIENTS WITH ALL, AML, CML, CLL, MYELOMA AND FORMS OF NHL, AFTER STEM CELL TRANSPLANTATION, AND FOR PATIENTS WITH BREAST, BRAIN, KIDNEY, COLORECTAL, HEAD-AND-NECK, LUNG, STOMACH, PROSTATE AND OVARIAN CANCERS, MELANOMA AS WELL AS SICKLE CELL DISEASE AND PERSISTENT HIV INFECTIONS. OTHER ACTIVE RESEARCH DIRECTIONS LLS-FUNDED RESEARCHERS ARE ALSO EXPLORING OTHER AREAS OF RESEARCH THAT HOLD PROMISE FOR PATIENTS: - NOVEL STEM CELL TRANSPLANTATION PROCEDURES: THESE INCLUDE SO-CALLED "MINI" TRANSPLANTS THAT USE LESS TOXIC PRE-TRANSPLANT TREATMENTS AND ENGINEERED DONOR CELLS THAT HELP REDUCE POST-TRANSPLANT COMPLICATIONS, MAKING THESE POTENTIALLY CURATIVE TREATMENTS AVAILABLE TO MORE PATIENTS. - IMMUNOTHERAPIES: INCLUDING ANTIBODIES, VACCINES AND ENGINEERED IMMUNE CELLS, THESE TARGETED THERAPIES HELP A PATIENT'S IMMUNE SYSTEM FIGHT INFECTIONS AND KILL RESIDUAL CANCER CELLS, PROLONGING REMISSIONS, AND PERHAPS ONE DAY REPLACING TOXIC CHEMOTHERAPIES. - DIAGNOSTICS: NEW TECHNOLOGIES MAKE IT POSSIBLE TO CHARACTERIZE THE ABNORMALITIES IN INDIVIDUAL CANCER CASES IN MOLECULAR DETAIL. THIS INFORMATION CAN BE USED TO HELP CHOOSE THE BEST POSSIBLE TREATMENT FOR EACH PATIENT, ESPECIALLY AS MORE TARGETED THERAPIES BECOME AVAILABLE. - QUALITY OF LIFE RESEARCH: THESE STUDIES INCREASE OUR UNDERSTANDING OF HOW SPECIFIC TREATMENTS CAN CAUSE DEBILITATING SIDE-EFFECTS, INCLUDING LATE-EFFECTS, AND WHICH PATIENTS ARE AT RISK FOR DEVELOPING THESE COMPLICATIONS, SO THAT THEY CAN BE BETTER MANAGED OR EVEN PREVENTED. DRIVING RESEARCH TO ADDRESS UNMET MEDICAL NEEDS LLS CONTINUES TO SOLICIT AND SUPPORT RESEARCH FOCUSED ON IMPROVING BLOOD CANCER PATIENTS' QUALITY OF LIFE AFTER TODAY'S CURATIVE THERAPIES. ALSO IN 2012, FOR THE SECOND YEAR, LLS ACTIVELY RECRUITED RESEARCH PROPOSALS IN THREE OTHER UNDERDEVELOPED RESEARCH AREAS IN WHICH PROGRESS IS LIKELY TO IMPROVE OUTCOMES FOR PATIENTS WITH PARTICULARLY URGENT NEEDS. NEW RESEARCH IS FOCUSED ON: - THE MALIGNANT STEM CELL IN AML AND MDS - NON-CUTANEOUS T-CELL LEUKEMIAS AND LYMPHOMAS - HIGH RISK MYELOMA CASES THE THERAPY ACCELERATION PROGRAM THIS STRATEGIC INITIATIVE WAS LAUNCHED IN 2007 TO MOVE NEW TREATMENTS AND DIAGNOSTICS THROUGH PRECLINICAL DEVELOPMENT AND CLINICAL TRIALS, FASTER. USING MILESTONE-DRIVEN CONTRACTS AND WORKING IN CONCERT WITH ACADEMIC INVESTIGATORS, MEDICAL CENTERS AND COMPANIES, LLS IS FURTHER BRIDGING THE GAP BETWEEN DISCOVERY AND HUMAN APPLICATIONS TO INCREASE THE LIKELIHOOD THAT NOVEL, POSSIBLY BREAKTHROUGH, TREATMENTS WILL BE AVAILABLE TO PATIENTS AS SOON AS POSSIBLE. THE PROGRAM INCLUDES: - THE ACADEMIC CONCIERGE DIVISION IDENTIFIES ESPECIALLY PROMISING LLS-FUNDED GRANT PROJECTS AND PROVIDES ADDITIONAL SUPPORT TO ADVANCE SELECTED PROJECTS TO THE PRODUCT STAGE. - THE BIOTECHNOLOGY ACCELERATOR DIVISION PARTNERS LLS WITH COMPANIES TO COMBINE SCIENTIFIC AND FINANCIAL RESOURCES AND ACCELERATE THE DEVELOPMENT OF POTENTIAL BLOOD CANCER THERAPIES THAT OTHERWISE MIGHT NOT BE PRIORITIZED BY THE COMPANY.. - THE CLINICAL TRIALS DIVISION BRINGS CLINICAL TRIALS TO BLOOD CANCER PATIENTS IN THEIR COMMUNITIES, INCLUDING UNDER-REPRESENTED POPULATIONS, AND WITH THE ULTIMATE GOAL OF INCREASING PATIENT ENROLLMENT IN BLOOD CANCER TRIALS. | Description |
Activity2 Activity2
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | 105745731 | Expense |
| Grants | 49018526 | Grants |
| Description | B) PATIENT & COMMUNITY SERVICES: AN ESTIMATED 1,012,533 PEOPLE ACROSS THE UNITED STATES (US) CURRENTLY BATTLE LEUKEMIA, LYMPHOMA AND MYELOMA. THE LEUKEMIA & LYMPHOMA SOCIETY (LLS) OFFERS A FREE, COMPREHENSIVE ARRAY OF SERVICES TO BLOOD CANCER PATIENTS AND THEIR FAMILIES, VOLUNTEER CAREGIVERS AND ADVOCATES, HEALTHCARE PROFESSIONALS AND THE PUBLIC. (CONTINUED ON SCHEDULE O) LLS IS COMMITTED TO PROVIDING THE MOST ACCURATE AND UP-TO-DATE BLOOD CANCER INFORMATION. PROFESSIONAL VOLUNTEER CLINICAL ADVISORS WORK WITH LLS STAFF TO REVIEW ALL OF THE INFORMATION LLS PROVIDES THROUGH HEALTHCARE PROFESSIONAL AND PATIENT EDUCATION PROGRAMS, PUBLICATIONS AND THE LLS WEBSITE. A NUMBER OF RESOURCES ARE AVAILABLE IN SPANISH FOR PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS. LLS PUBLISHES AN ANNUAL COMPILATION OF DATA AVAILABLE FOR BLOOD CANCERS, INCLUDING THE ESTIMATED NUMBERS OF NEW BLOOD CANCER CASES AND DEATHS, THE MOST RECENT STATISTICS AVAILABLE FOR INCIDENCE, MORTALITY AND SURVIVAL; AND CURRENT AND ACCURATE INFORMATION ABOUT SYMPTOMS, RISK FACTORS AND TREATMENT. PUBLICATIONS: AN EXTENSIVE CATALOG OF EDUCATION MATERIALS IS OFFERED FREE-OF-CHARGE TO PATIENTS AND HEALTHCARE PROFESSIONALS. EACH YEAR, LLS DISTRIBUTES BOOKLETS, BROCHURES, FACT SHEETS, EDUCATION PROGRAM TRANSCRIPTS AND DVDS THROUGH THE INFORMATION RESOURCE CENTER AND LLS CHAPTERS. MANY MATERIALS ARE ALSO AVAILABLE TO VIEW AND DOWNLOAD AT WWW.LLS.ORG/RESOURCECENTER. DOWNLOADABLE MATERIALS ARE AVAILABLE IN ENGLISH AND SPANISH. - 1,077,533 PRINTED BOOKLETS, BROCHURES, FACT SHEETS, EDUCATION PROGRAM TRANSCRIPTS AND DVDS DISTRIBUTED IN 2012 FINANCIAL ASSISTANCE IN 2012, A COMBINED 48,018,526 DOLLARS WAS AWARDED TO PATIENTS THROUGH THE LLS PATIENT FINANCIAL AID (3,057,200) AND CO-PAY ASSISTANCE PROGRAMS (45,961,326). PATIENT FINANCIAL AID PROGRAM FOR MORE THAN 46 YEARS, LLS HAS HELPED PATIENTS DEMONSTRATING SIGNIFICANT NEED TO OBTAIN FINANCIAL ASSISTANCE TO COVER A PORTION OF THEIR TREATMENT COSTS. THE LLS PATIENT FINANCIAL AID PROGRAM PROVIDES A LIMITED AMOUNT OF FINANCIAL ASSISTANCE TO HELP PATIENTS WITH SIGNIFICANT FINANCIAL NEED AND WHO ARE UNDER A DOCTOR'S CARE FOR A CONFIRMED BLOOD CANCER DIAGNOSIS. PATIENT FINANCIAL AID FUNDS ARE SUBJECT TO AVAILABILITY. - 30,603 PATIENTS RECEIVED FINANCIAL AID IN 2012 CO-PAY ASSISTANCE PROGRAM THIS CO-PAY ASSISTANCE PROGRAM HELPS PATIENTS WITH MANY KINDS OF BLOOD CANCERS MEET THEIR HEALTH INSURANCE OR MEDICARE PLAN PART B OR D PREMIUMS OR CO-PAYMENT OBLIGATIONS RELATED TO TREATING THEIR CANCER. PATIENTS WITH PRESCRIPTION DRUG COVERAGE, MEDICARE BENEFICIARIES UNDER MEDICARE PART B AND/OR MEDICARE PART D, MEDICARE SUPPLEMENTARY HEALTH INSURANCE OR MEDICARE ADVANTAGE SHOULD CHECK WITH LLS TO SEE IF THEY MEET ELIGIBILITY REQUIREMENTS TO RECEIVE FINANCIAL SUPPORT. CO-PAY ASSISTANCE IS SUBJECT TO FUND AVAILABILITY BY SPECIFIC BLOOD CANCER DIAGNOSIS. FOR MORE INFORMATION CALL, (877) LLS-COPAY (877) 557-2672 OR VISIT WWW.LLS.ORG/COPAY. - 13,971 PATIENTS RECEIVED LLS CO-PAY ASSISTANCE IN 2012 COMMUNITY PROGRAMS EACH LLS CHAPTER OFFICE IS STAFFED WITH A PATIENT SERVICES MANAGER (PSM) WHO OVERSEES SERVICES TO PATIENTS AND THEIR FAMILIES, CAREGIVERS AND HEALTHCARE PROFESSIONALS. PSMS ARE HEALTHCARE PROFESSIONALS, OFTEN WITH A BACKGROUND IN ONCOLOGY NURSING OR SOCIAL WORK. PSMS SERVE AS LIAISONS WITH COMMUNITY AND REGIONAL ONCOLOGY/HEMATOLOGY HEALTHCARE PROFESSIONALS AND TREATMENT CENTERS.COMMUNITY-BASED EDUCATION AND OUTREACH, SUPPORT AND PUBLIC POLICY AND ADVOCACY PROGRAMS ARE AVAILABLE. - 43,282 PATIENT AND CAREGIVER PARTICIPANTS IN 2012 - 11,424 HEALTHCARE PROFESSIONAL PARTICIPANTS IN 2012 PROGRAMS FOR CHILDREN AND YOUNG ADULTS THE TRISH GREENE BACK TO SCHOOL PROGRAM FOR CHILDREN WITH CANCER FOCUSES ON INCREASING COMMUNICATION AMONG HEALTHCARE PROFESSIONALS, PARENTS, PATIENTS AND SCHOOL PERSONNEL TO SUPPORT CHILDREN, ADOLESCENTS AND YOUNG ADULTS LIVING WITH CANCER. PRINTED LITERATURE, VIDEOS AND OTHER MATERIALS TO AID THE PROCESS ARE AVAILABLE IN COMMUNITIES THROUGHOUT THE US AND CANADA VIA LLS CHAPTER OFFICES. THE PROGRAM INCLUDES STAYING CONNECTED: FACILITATING THE LEARNING EXPERIENCE DURING AND AFTER CANCER TREATMENT. THIS EDUCATION PROGRAM FOR SCHOOL PERSONNEL, HEALTHCARE PROFESSIONALS AND PARENTS DESCRIBES PHYSICAL, COGNITIVE AND PSYCHOSOCIAL SHORT-AND LONG-TERM EFFECTS THAT CHILDREN, ADOLESCENTS AND YOUNG ADULTS MAY EXPERIENCE DURING AND AFTER TREATMENT. THE PROGRAM OFFERS GUIDANCE AND NUMEROUS RESOURCES TO HELP CHILDREN, ADOLESCENTS AND YOUNG ADULTS CONTINUE THEIR EDUCATION DURING AND AFTER TREATMENT. - 2,957 SCHOOL PERSONNEL, HEALTHCARE PROFESSIONALS AND PARENTS PARTICIPATED IN THE 81 STAYING CONNECTED PROGRAMS ACROSS THE US AND CANADA IN 2012. FAMILY SUPPORT GROUPS LLS HAS DEVELOPED 419 FAMILY SUPPORT GROUPS AT CHAPTERS THROUGHOUT THE US AND CANADA. LLS ALSO HAS 786 VOLUNTEER SUPPORT GROUP FACILITATORS WITH BACKGROUNDS IN ONCOLOGY NURSING OR SOCIAL WORK. GROUPS ARE GUIDED BY TWO VOLUNTEER ONCOLOGY HEALTH PROFESSIONALS, PROVIDING INFORMATION AND SUPPORT AND ENCOURAGING GREATER COMMUNICATION AMONG PATIENTS, FAMILIES, FRIENDS AND HEALTHCARE PROFESSIONALS. - 12,113 PARTICIPANTS IN FAMILY SUPPORT GROUPS IN 2012 PATTI ROBINSON KAUFMANN FIRST CONNECTION PROGRAM FIRST CONNECTION IS A PROGRAM THAT LINKS NEWLY DIAGNOSED PATIENTS TO A PEER VOLUNTEER WHO HAS EXPERIENCED A SIMILAR DIAGNOSIS. A TRAINED PATIENT-VOLUNTEER CURRENTLY IN REMISSION CONTACTS THE NEW PATIENT TO SHARE INFORMATION AND SUPPORT. THIS PROGRAM IS AVAILABLE THROUGH LLS CHAPTERS. - 6,050 FIRST CONNECTIONS IN 2012 | Description |
Activity3 Activity3
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | 38321146 | Expense |
| Description | C) PUBLIC HEALTH EDUCATION: INFORMATION AND EDUCATION INFORMATION RESOURCE CENTER PAYING FOR MEDICAL CARE, MAKING TREATMENT CHOICES, COMMUNICATING WITH HEALTHCARE PROVIDERS, FAMILY MEMBERS AND FRIENDS-THESE ARE SOME OF THE STRESSES THAT COME WITH A CANCER DIAGNOSIS. (CONTINUED ON SCHEDULE O) LLS INFORMATION SPECIALISTS ARE MASTER'S LEVEL ONCOLOGY SOCIAL WORKERS, NURSES AND HEALTH EDUCATORS WHO PROVIDE HELP WITH DISEASE, TREATMENT AND CLINICAL TRIAL INFORMATION AND SUPPORT. LLS INFORMATION SPECIALISTS CONDUCT CLINICAL-TRIAL SEARCHES TO HELP PATIENTS WORK WITH THEIR DOCTORS TO FIND OUT ABOUT SPECIFIC CLINICAL TRIALS. PATIENTS, FAMILIES AND HEALTHCARE PROFESSIONALS MAY SPEAK TO AN INFORMATION SPECIALIST AT (800) 955-4572 MONDAY THROUGH FRIDAY, 9 A.M. TO 6 P.M., ET, EMAIL INFOCENTER@LLS.ORG OR CHAT ONE-ON-ONE VIA THE LLS WEBSITE. THE INFORMATION RESOURCE CENTER OFFERS TRANSLATION SERVICES IN MORE THAN 165 LANGUAGES. - 60,012 INQUIRIES IN 2012 THE LLS WEBSITE THE LLS WEBSITE, WWW.LLS.ORG, FULFILLS A WIDE VARIETY OF EDUCATION AND INFORMATION NEEDS. VISITORS CAN PERSONALIZE THEIR WEB PAGES TO KEEP CURRENT WITH DISEASE-SPECIFIC UPDATES AND COMMUNITY EDUCATION AND SUPPORT ACTIVITIES. THE WEBSITE PROVIDES ACCESS TO LLS PROGRAMS AND SERVICES, INCLUDING CO-PAY ASSISTANCE, PATIENT FINANCIAL AID, THE MOST CURRENT AND ACCURATE INFORMATION AND STATISTICS, WEEKLY FACILITATED ONLINE CHATS, NATIONAL TELEPHONE AND WEB EDUCATION PROGRAMS, PUBLICATIONS IN ENGLISH AND SPANISH, AND CLINICAL-TRIAL SEARCHES VIA AN ONLINE CLINICAL-TRIAL SEARCH SERVICE THAT OFFERS PATIENTS AND CAREGIVERS IMMEDIATE ACCESS TO LISTINGS OF BLOOD CANCER CLINICAL TRIALS. PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS CAN INTERACT WITH LLS AND ONE ANOTHER THROUGH SOCIAL NETWORKING, PODCASTS AND ENEWSLETTERS. NATIONAL TELEPHONE/ WEB EDUCATION PROGRAMS LLS SPONSORS TELEPHONE AND WEB EDUCATION PROGRAMS FOR PATIENTS, CAREGIVERS, SURVIVORS AND HEALTHCARE PROFESSIONALS ABOUT LEUKEMIA, LYMPHOMA, MYELOMA AND MYELODYSPLASTIC SYNDROMES. IN 2012, 10 LLS NATIONAL EDUCATION PROGRAMS FEATURED DISEASE-SPECIFIC UPDATES AND INFORMATION ABOUT TREATMENT OPTIONS FROM WORLD RENOWNED CLINICAL EXPERTS. OPPORTUNITIES ARE PROVIDED TO ASK QUESTIONS OF EXPERTS DURING THESE PROGRAMS. MANY OF THESE PROGRAMS INCLUDE CONTINUING EDUCATION CREDITS FOR NURSES AND SOCIAL WORKERS. LLS ALSO SPONSORS A RANGE OF PROFESSIONAL EDUCATION PROGRAMS. RECENT PROGRAMS EXPLORED COMMUNICATION AMONG PRIMARY CARE PROVIDERS AND HEMATOLOGISTS/ONCOLOGISTS IN MANAGING PATIENTS WITH HEMATOLOGIC CANCER AND NURSING MANAGEMENT OF CHALLENGING SIDE EFFECTS. UPCOMING PROGRAMS ARE POSTED AT WWW.LLS.ORG/PROGRAMS AND ARCHIVES OF PAST PROGRAMS ARE AVAILABLE AT WWW.LLS.ORG/PASTPROGRAMS. PROFESSIONAL EDUCATION PROGRAMS ARE AVAILABLE AT WWW.LLS.ORG/PROFESSIONALED. LLS ALSO OFFERS DISEASE-SPECIFIC WEBCASTS PRESENTED BY WORLD RENOWNED CLINICAL EXPERTS. THESE CAN BE ACCESSED AT WWW.LLS.ORG/WEBCASTS. | Description |
Activity Other ActivityOther
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | 8532346 | Expense |
| Description | D) PROFESSIONAL EDUCATION: LLS SERVES THE EDUCATIONAL NEEDS OF THE MEDICAL AND RESEARCH COMMUNITY THROUGH A NUMBER OF PROFESSIONAL EDUCATION SYMPOSIA OFFERED THROUGHOUT THE YEAR. THE EDUCATIONAL PROGRAM OFFERS VARYING FORMATS TO FACILITATE THE EXCHANGE OF INFORMATION AND IDEAS ON THE NEWEST DEVELOPMENTS IN CANCER RESEARCH AND TREATMENT. | Description |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Of Other Program Service Exp | 8532346 | TotalOfOtherProgramServiceExp |
| Total Program Service Expense | 222923399 | TotalProgramServiceExpense |
| Described In501 C3 | true | DescribedIn501C3 |
| Schedule B Required | true | ScheduleBRequired |
| Political Activities | false | PoliticalActivities |
| Lobbying Activities | true | LobbyingActivities |
| Subject To Proxy Tax | false | SubjectToProxyTax |
| Donor Advised Funds | false | DonorAdvisedFunds |
| Conservation Easements | false | ConservationEasements |
| Collections Of Art | true | CollectionsOfArt |
| Credit Counseling | false | CreditCounseling |
| Term Or Permanent Endowments | true | TermOrPermanentEndowments |
| Report Land Bldg Equip | true | ReportLandBldgEquip |
| Report Invest Oth Securities | true | ReportInvestOthSecurities |
| Report Prog Rel Invest | false | ReportProgRelInvest |
| Report Other Assets | false | ReportOtherAssets |
| Report Other Liabilities | false | ReportOtherLiabilities |
| Report Fin48 Footnote | true | ReportFin48Footnote |
| Independent Audit Financial Stmt | false | IndependentAuditFinancialStmt |
| Consolidated Audit Financial Stmt | true | ConsolidatedAuditFinancialStmt |
| School | false | School |
| Foreign Office | true | ForeignOffice |
| Foreign Activities | true | ForeignActivities |
| More Than5000 K To Organizations | true | MoreThan5000KToOrganizations |
| More Than5000 K To Individuals | false | MoreThan5000KToIndividuals |
| Professional Fundraising | true | ProfessionalFundraising |
| Fundraising Activities | true | FundraisingActivities |
| Gaming | true | Gaming |
| Hospital | false | Hospital |
| Grants To Organizations | true | GrantsToOrganizations |
| Grants To Individuals | true | GrantsToIndividuals |
| Schedule J Required | true | ScheduleJRequired |
| Tax Exempt Bonds | false | TaxExemptBonds |
| Excess Benefit Transaction | false | ExcessBenefitTransaction |
| Prior Excess Benefit Transaction | false | PriorExcessBenefitTransaction |
| Loan To Officer Or DQP | false | LoanToOfficerOrDQP |
| Grant To Related Person | false | GrantToRelatedPerson |
| Bsnss Rltnshp With Organization | false | BsnssRltnshpWithOrganization |
| Bsnss Rltnshp Thru Family Member | false | BsnssRltnshpThruFamilyMember |
| Officer Entity With Bsnss Rltnshp | false | OfficerEntityWithBsnssRltnshp |
| Deductible Non Cash Contributions | true | DeductibleNonCashContributions |
| Deductible Contributions Of Art | false | DeductibleContributionsOfArt |
| Terminated | false | Terminated |
| Partial Liquidation | false | PartialLiquidation |
| Disregarded Entity | false | DisregardedEntity |
| Related Entity | true | RelatedEntity |
| Related Org Controlled Entity | true | RelatedOrgControlledEntity |
| Transaction Related Entity | true | TransactionRelatedEntity |
| Transfers To Exempt Non Chrtbl Org | false | TransfersToExemptNonChrtblOrg |
| Activities Conducted Partnership | false | ActivitiesConductedPartnership |
| Schedule O Required | true | ScheduleORequired |
| Number Forms Transmitted With1096 | 1198 | NumberFormsTransmittedWith1096 |
| Number W2 G Included | 22 | NumberW2GIncluded |
| Compliance With Backup Witholding | true | ComplianceWithBackupWitholding |
| Number Of Employees | 1942 | NumberOfEmployees |
| Employment Tax Returns Filed | true | EmploymentTaxReturnsFiled |
| Unrelated Business Income | false | UnrelatedBusinessIncome |
| Foreign Financial Account | true | ForeignFinancialAccount |
| Name Of Foreign Country | CA | NameOfForeignCountry |
| Prohibited Tax Shelter Trans | false | ProhibitedTaxShelterTrans |
| Taxable Party Notification | false | TaxablePartyNotification |
| Non Deductible Contributions | true | NonDeductibleContributions |
| Non Deductible Disclosure | true | NonDeductibleDisclosure |
| Quid Pro Quo Contributions | true | QuidProQuoContributions |
| Quid Pro Quo Disclosure | true | QuidProQuoDisclosure |
| Form8282 Property Disposed Of | false | Form8282PropertyDisposedOf |
| Funds To Pay Premiums | false | FundsToPayPremiums |
| Premiums Paid | false | PremiumsPaid |
| Indoor Tanning Services | false | IndoorTanningServices |
| Info In Schedule O Part VI | X | InfoInScheduleOPartVI |
| Nbr Voting Governing Body Members | 26 | NbrVotingGoverningBodyMembers |
| Number Independent Voting Members | 26 | NumberIndependentVotingMembers |
| Family Or Business Relationship | false | FamilyOrBusinessRelationship |
| Delegation Of Management Duties | false | DelegationOfManagementDuties |
| Changes To Organizing Docs | false | ChangesToOrganizingDocs |
| Material Diversion Or Misuse | false | MaterialDiversionOrMisuse |
| Members Or Stockholders | true | MembersOrStockholders |
| Election Of Board Members | true | ElectionOfBoardMembers |
| Decisions Subject To Approval | true | DecisionsSubjectToApproval |
| Minutes Of Governing Body | true | MinutesOfGoverningBody |
| Minutes Of Committees | true | MinutesOfCommittees |
| Officer Mailing Address | false | OfficerMailingAddress |
| Local Chapters | true | LocalChapters |
| Policies Reference Chapters | true | PoliciesReferenceChapters |
| Form990 Provided To Governing Body | true | Form990ProvidedToGoverningBody |
| Conflict Of Interest Policy | true | ConflictOfInterestPolicy |
| Annual Disclosure Covered Persons | true | AnnualDisclosureCoveredPersons |
| Regular Monitoring Enforcement | true | RegularMonitoringEnforcement |
| Whistleblower Policy | true | WhistleblowerPolicy |
| Document Retention Policy | true | DocumentRetentionPolicy |
| Compensation Process CEO | true | CompensationProcessCEO |
| Compensation Process Other | true | CompensationProcessOther |
| Investment In Joint Venture | false | InvestmentInJointVenture |
| States Where Copy Of Return Is Filed | AK | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | AL | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | AR | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | AZ | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | CA | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | CO | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | CT | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | DE | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | DC | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | FL | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | GA | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | HI | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | ID | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | IL | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | IN | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | KS | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | KY | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | LA | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | MA | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | MD | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | ME | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | MI | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | MN | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | MO | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | MS | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | NH | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | NJ | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | NM | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | NE | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | NY | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | OH | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | OK | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | OR | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | PA | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | PR | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | RI | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | SC | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | TN | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | UT | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | VA | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | WA | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | WI | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | WV | StatesWhereCopyOfReturnIsFiled |
| Own Website | X | OwnWebsite |
| Upon Request | X | UponRequest |
The Books Are In Care Of TheBooksAreInCareOf
| Field | Value | IRS element (for citing) |
|---|---|---|
| Name Person | JAMES T NANGLE | NamePerson |
| Telephone Number | 9149495213 | TelephoneNumber |
Address US AddressUS
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 1311 MAMARONECK AVENUE | AddressLine1 |
| City | WHITE PLAINS | City |
| State | NY | State |
| ZIP Code | 10605 | ZIPCode |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Info In Schedule O Part VII | X | InfoInScheduleOPartVII |
Form990 Part VII Section A Form990PartVIISectionA (35 entries)
| TitleTitle | Average Hours Per WeekAverageHoursPerWeek | Individual Trustee Or DirectorIndividualTrusteeOrDirector | Reportable Comp From OrganizationReportableCompFromOrganization | Reportable Comp From Related OrgsReportableCompFromRelatedOrgs | Other CompensationOtherCompensation | OfficerOfficer | Highest Compensated EmployeeHighestCompensatedEmployee | FormerFormer |
|---|---|---|---|---|---|---|---|---|
| JAMES A BECK | ||||||||
| BOD MEMBER | 2.00 | X | 0 | 0 | 0 | |||
| WILLIAM G BEHNKE | ||||||||
| BOD MEMBER | 2.00 | X | 0 | 0 | 0 | |||
| JORGE L BENITEZ | ||||||||
| BOD MEMBER | 2.00 | X | 0 | 0 | 0 | |||
| PETER B BROCK | ||||||||
| BOD MEMBER | 2.00 | X | 0 | 0 | 0 | |||
| A DANA CALLOW JR | ||||||||
| BOD MEMBER | 2.00 | X | 0 | 0 | 0 | |||
| ELIZABETH J CLARK | ||||||||
| BOD MEMBER | 2.00 | X | 0 | 0 | 0 | |||
| JORGE CORTES MD | ||||||||
| BOD MEMBER | 2.00 | X | 0 | 0 | 0 | |||
| JAMES H DAVIS PHD | ||||||||
| BOD MEMBER | 2.00 | X | 0 | 0 | 0 | |||
| BERNARD H GARIL | ||||||||
| BOD MEMBER | 2.00 | X | 0 | 0 | 0 | |||
| D GARY GILLILAND MD PHD | ||||||||
| BOD MEMBER | 2.00 | X | 0 | 0 | 0 | |||
| PAMELA JO HAYLOCK | ||||||||
| BOD MEMBER | 2.00 | X | 0 | 0 | 0 | |||
| RAANAN HOROWITZ | ||||||||
| BOD MEMBER | 2.00 | X | 0 | 0 | 0 | |||
| RICHARD M JEANNERET | ||||||||
| BOD MEMBER | 2.00 | X | 0 | 0 | 0 | |||
| ARMAND KEATING MD | ||||||||
| BOD MEMBER | 2.00 | X | 0 | 0 | 0 | |||
| JOSEPH B KELLEY | ||||||||
| BOD MEMBER | 2.00 | X | 0 | 0 | 0 | |||
| MARIE V MCDEMMOND | ||||||||
| BOD MEMBER | 2.00 | X | 0 | 0 | 0 | |||
| RODMAN N MYERS | ||||||||
| BOD MEMBER | 2.00 | X | 0 | 0 | 0 | |||
| STEVEN T ROSENMDFACP | ||||||||
| BOD MEMBER | 2.00 | X | 0 | 0 | 0 | |||
| KENNETH M SCHWARTZ | ||||||||
| BOD MEMBER | 2.00 | X | 0 | 0 | 0 | |||
| KATHRYN C VECELLIO | ||||||||
| BOD MEMBER | 2.00 | X | 0 | 0 | 0 | |||
| WILLIAM M WARD JR | ||||||||
| BOD MEMBER | 2.00 | X | 0 | 0 | 0 | |||
| LOUISE E WARNER | ||||||||
| BOD MEMBER | 2.00 | X | 0 | 0 | 0 | |||
| MATTHEW J WINTER | ||||||||
| BOD MEMBER | 2.00 | X | 0 | 0 | 0 | |||
| JOHN WALTER | ||||||||
| PRESIDENT & | 45.00 | 581743 | 0 | 53168 | X | |||
| JAMES T NANGLE | ||||||||
| SVP&CFO | 45.00 | 244684 | 0 | 45548 | X | |||
| SCOTT A CARROLL | ||||||||
| CHAIR | 2.00 | 0 | 0 | 0 | X | |||
| TIMOTHY DURST | ||||||||
| VICE CHAIR | 2.00 | 0 | 0 | 0 | X | |||
| STEVEN HOOKER | ||||||||
| SECRETARY/TR | 2.00 | 0 | 0 | 0 | X | |||
| LOUIS DEGENNARO | ||||||||
| CHIEF MISSIO | 45.00 | 382478 | 0 | 39732 | X | |||
| NANCY KLEIN | ||||||||
| CHIEF MARKET | 45.00 | 374498 | 0 | 46770 | X | |||
| RICHARD WINNEKER | ||||||||
| SVP RESEARCH | 45.00 | 269975 | 0 | 6410 | X | |||
| DAVID TIMKO | ||||||||
| SVP VOLUNTEE | 45.00 | 247798 | 0 | 38657 | X | |||
| MICHAEL OSSO | ||||||||
| SVP REVENUE | 45.00 | 245194 | 0 | 36231 | X | |||
| JAY SILVER | ||||||||
| BOD MEMBER | 2.00 | 0 | 0 | 0 | X | |||
| DEREK RAGHAVAN | ||||||||
| BOD MEMBER | 2.00 | 0 | 0 | 0 | X | |||
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Reportable Comp From Org | 2346370 | TotalReportableCompFromOrg |
| Total Other Compensation | 266516 | TotalOtherCompensation |
| Number Individuals GT100 K | 127 | NumberIndividualsGT100K |
| Formers Listed | true | FormersListed |
| Total Comp GT150 K | true | TotalCompGT150K |
| Compensation From Other Sources | false | CompensationFromOtherSources |
Contractor Compensation ContractorCompensation (5 entries)
| Address Line1AddressOfContractor/AddressUS/AddressLine1 | CityAddressOfContractor/AddressUS/City | StateAddressOfContractor/AddressUS/State | ZIP CodeAddressOfContractor/AddressUS/ZIPCode | Description Of ServicesDescriptionOfServices | CompensationCompensation |
|---|---|---|---|---|---|
| PARADYSZ MATERA | |||||
| 5 HANOVER SQUARE | NEW YORK | NY | 10004 | FUNDRAISING SER | 2641112 |
| DIRECT PRINT COMMUNICATIONS | |||||
| 201 EAST SANDPOINTE | SANTA ANNA | CA | 92707 | FUNDRASING SERV | 2324784 |
| INFOCISION CORPORATION | |||||
| 325 SPRINGSIDE DRIVE | AKRON | OH | 44333 | FUNDRAISING SER | 2010620 |
| MSP | |||||
| PO BOX 641114 | PITTSBURGH | PA | 15264 | FUNDRAISING SER | 1954908 |
| ROBERT MICHAEL EDUCATIONAL INSTITUT | |||||
| 101 LAUREL ROAD | VOORHESS | NJ | 08043 | EDUCATIONAL SER | 1502644 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Number Of Contractors GT100 K | 72 | NumberOfContractorsGT100K |
| Federated Campaigns | 2413381 | FederatedCampaigns |
| Fundraising Events | 157234611 | FundraisingEvents |
| Government Grants | 14969 | GovernmentGrants |
| All Other Contributions | 123009112 | AllOtherContributions |
| Noncash Contributions | 803655 | NoncashContributions |
| Total Contributions | 282672073 | TotalContributions |
Investment Income InvestmentIncome
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | 2703601 | TotalRevenueColumn |
| Exclusion | $2,703,601 | ExclusionAmount |
Royalties Revenue RoyaltiesRevenue
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | 1445 | TotalRevenueColumn |
| Exclusion | $1,445 | ExclusionAmount |
Gross Amount Sales Assets GrossAmountSalesAssets
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | 91812719 | Securities |
Less Cost Oth Basis Sales Expenses LessCostOthBasisSalesExpenses
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | 86476441 | Securities |
Gain Or Loss GainOrLoss
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | 5336278 | Securities |
Net Gain Or Loss Investments NetGainOrLossInvestments
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | 5336278 | TotalRevenueColumn |
| Exclusion | $5,336,278 | ExclusionAmount |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Gross Income Fundraising Events | 36867938 | GrossIncomeFundraisingEvents |
| Cntrbtns Rprtd Fundraising Events | 157234611 | CntrbtnsRprtdFundraisingEvents |
| Fundraising Direct Expenses | 36867938 | FundraisingDirectExpenses |
| Gross Income Gaming | 940518 | GrossIncomeGaming |
| Gaming Direct Expenses | 332966 | GamingDirectExpenses |
Net Income From Gaming NetIncomeFromGaming
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | 607552 | TotalRevenueColumn |
| Related Or Exempt Function Income | 607552 | RelatedOrExemptFunctionIncome |
Other Revenue Misc OtherRevenueMisc (2 entries)
| DescriptionDescription | Business CodeBusinessCode | Total Revenue ColumnTotalRevenueColumn | ExclusionExclusionAmount |
|---|---|---|---|
| GRANT TERMINATION | 541900 | 1477090 | $1,477,090 |
| OTHER MISCELLANEOUS | 900099 | 24954 | $24,954 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Other Revenue | 1502044 | TotalOtherRevenue |
Total Revenue TotalRevenue
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | 292822993 | TotalRevenueColumn |
| Related Or Exempt Function Income | 607552 | RelatedOrExemptFunctionIncome |
| Exclusion | $9,543,368 | ExclusionAmount |
Grants To Domestic Orgs GrantsToDomesticOrgs
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 60600563 | Total |
| Program Services | 60600563 | ProgramServices |
Grants To Domestic Individuals GrantsToDomesticIndividuals
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 49018526 | Total |
| Program Services | 49018526 | ProgramServices |
Foreign Grants ForeignGrants
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 6112538 | Total |
| Program Services | 6112538 | ProgramServices |
Comp Current Officers Directors CompCurrentOfficersDirectors
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 934832 | Total |
| Program Services | 693373 | ProgramServices |
| Management And General | 108381 | ManagementAndGeneral |
| Fundraising | 133078 | Fundraising |
Other Salaries And Wages OtherSalariesAndWages
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 65894279 | Total |
| Program Services | 48874387 | ProgramServices |
| Management And General | 7639571 | ManagementAndGeneral |
| Fundraising | 9380321 | Fundraising |
Pension Plan Contributions PensionPlanContributions
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 3977818 | Total |
| Program Services | 2789860 | ProgramServices |
| Management And General | 475995 | ManagementAndGeneral |
| Fundraising | 711963 | Fundraising |
Other Employee Benefits OtherEmployeeBenefits
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 11297662 | Total |
| Program Services | 7923662 | ProgramServices |
| Management And General | 1351904 | ManagementAndGeneral |
| Fundraising | 2022096 | Fundraising |
Payroll Taxes PayrollTaxes
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 4671886 | Total |
| Program Services | 3276647 | ProgramServices |
| Management And General | 559048 | ManagementAndGeneral |
| Fundraising | 836191 | Fundraising |
Fees For Services Legal FeesForServicesLegal
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 657011 | Total |
| Program Services | 373063 | ProgramServices |
| Management And General | 102391 | ManagementAndGeneral |
| Fundraising | 181557 | Fundraising |
Fees For Services Accounting FeesForServicesAccounting
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 256761 | Total |
| Program Services | 145793 | ProgramServices |
| Management And General | 40014 | ManagementAndGeneral |
| Fundraising | 70954 | Fundraising |
Fees For Services Lobbying FeesForServicesLobbying
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 568404 | Total |
| Program Services | 322748 | ProgramServices |
| Management And General | 88583 | ManagementAndGeneral |
| Fundraising | 157073 | Fundraising |
Fees For Services Prof Fundraising FeesForServicesProfFundraising
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 10175403 | Total |
| Fundraising | 10175403 | Fundraising |
Fees For Services Invst Mgmnt Fees FeesForServicesInvstMgmntFees
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 598320 | Total |
| Program Services | 339738 | ProgramServices |
| Management And General | 93244 | ManagementAndGeneral |
| Fundraising | 165338 | Fundraising |
Fees For Services Other FeesForServicesOther
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 14166395 | Total |
| Program Services | 8043931 | ProgramServices |
| Management And General | 2207736 | ManagementAndGeneral |
| Fundraising | 3914728 | Fundraising |
Advertising Advertising
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 5841570 | Total |
| Program Services | 2397725 | ProgramServices |
| Management And General | 1155048 | ManagementAndGeneral |
| Fundraising | 2288797 | Fundraising |
Information Technology InformationTechnology
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 4127452 | Total |
| Program Services | 2343640 | ProgramServices |
| Management And General | 643234 | ManagementAndGeneral |
| Fundraising | 1140578 | Fundraising |
Occupancy Occupancy
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 8500974 | Total |
| Program Services | 6090214 | ProgramServices |
| Management And General | 1018748 | ManagementAndGeneral |
| Fundraising | 1392012 | Fundraising |
Travel Travel
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 3864333 | Total |
| Program Services | 2773731 | ProgramServices |
| Management And General | 479994 | ManagementAndGeneral |
| Fundraising | 610608 | Fundraising |
Conferences Meetings ConferencesMeetings
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 4068549 | Total |
| Program Services | 3420109 | ProgramServices |
| Management And General | 289541 | ManagementAndGeneral |
| Fundraising | 358899 | Fundraising |
Depreciation Depletion DepreciationDepletion
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 2719990 | Total |
| Program Services | 1757140 | ProgramServices |
| Management And General | 343440 | ManagementAndGeneral |
| Fundraising | 619410 | Fundraising |
Insurance Insurance
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 523304 | Total |
| Program Services | 365915 | ProgramServices |
| Management And General | 55456 | ManagementAndGeneral |
| Fundraising | 101933 | Fundraising |
Other Expenses OtherExpenses (4 entries)
| DescriptionDescription | TotalTotal | Program ServicesProgramServices | Management And GeneralManagementAndGeneral | FundraisingFundraising |
|---|---|---|---|---|
| PRINTING | 16202162 | 6650325 | 3203634 | 6348203 |
| POSTAGE | 10330621 | 3787901 | 1588979 | 4953741 |
| MISCELLANEOUS | 3514511 | 2500416 | 410393 | 603702 |
| TELEPHONE | 3475172 | 2200173 | 298479 | 976520 |
All Other Expenses AllOtherExpenses
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 295478 | Total |
| Program Services | 121281 | ProgramServices |
| Management And General | 58425 | ManagementAndGeneral |
| Fundraising | 115772 | Fundraising |
Total Functional Expenses TotalFunctionalExpenses
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 292394514 | Total |
| Program Services | 222923399 | ProgramServices |
| Management And General | 22212238 | ManagementAndGeneral |
| Fundraising | 47258877 | Fundraising |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Joint Costs | X | JointCosts |
Total Joint Costs TotalJointCosts
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 19790406 | Total |
| Program Services | 9427344 | ProgramServices |
| Fundraising | 10363062 | Fundraising |
Savings And Temp Cash Investments SavingsAndTempCashInvestments
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 15624105 | BOY |
| EOY | 23567530 | EOY |
Pledges And Grants Receivable PledgesAndGrantsReceivable
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 19055089 | BOY |
| EOY | 5178782 | EOY |
Accounts Receivable AccountsReceivable
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 328134 | BOY |
| EOY | 264507 | EOY |
Prepaid Expenses Deferred Charges PrepaidExpensesDeferredCharges
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 4423864 | BOY |
| EOY | 5875009 | EOY |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Land Buildings Equipment Basis | 17733329 | LandBuildingsEquipmentBasis |
| Land Bldg Equipment Accum Deprec | 11092269 | LandBldgEquipmentAccumDeprec |
Land Buildings Equipment Basis Net LandBuildingsEquipmentBasisNet
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 5182309 | BOY |
| EOY | 6641060 | EOY |
Investments Pub Traded Securities InvestmentsPubTradedSecurities
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 128104890 | BOY |
| EOY | 138026930 | EOY |
Investments Other Securities InvestmentsOtherSecurities
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 51553483 | BOY |
| EOY | 43892106 | EOY |
Total Assets TotalAssets
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 224271874 | BOY |
| EOY | 223445924 | EOY |
Accounts Payable Accrued Expenses AccountsPayableAccruedExpenses
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 17155530 | BOY |
| EOY | 19660610 | EOY |
Grants Payable GrantsPayable
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 70833146 | BOY |
| EOY | 72815341 | EOY |
Deferred Revenue DeferredRevenue
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 16499305 | BOY |
| EOY | 16921194 | EOY |
Total Liabilities TotalLiabilities
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 104487981 | BOY |
| EOY | 109397145 | EOY |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Follow SFAS117 | X | FollowSFAS117 |
Unrestricted Net Assets UnrestrictedNetAssets
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 93670008 | BOY |
| EOY | 100978174 | EOY |
Temporarily Restricted Net Assets TemporarilyRestrictedNetAssets
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 23328394 | BOY |
| EOY | 10221074 | EOY |
Permanently Restricted Net Assets PermanentlyRestrictedNetAssets
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 2785491 | BOY |
| EOY | 2849531 | EOY |
Total Net Assets Fund Balances TotalNetAssetsFundBalances
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 119783893 | BOY |
| EOY | 114048779 | EOY |
Total Liab Net Assets Fund Balances TotalLiabNetAssetsFundBalances
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 224271874 | BOY |
| EOY | 223445924 | EOY |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Info In Schedule O Part XI | X | InfoInScheduleOPartXI |
| Reconcilation Revenue Expenses | 428479 | ReconcilationRevenueExpenses |
| Reconcilation Other Changes | -6163593 | ReconcilationOtherChanges |
| Info In Schedule O Part XII | X | InfoInScheduleOPartXII |
| Method Of Accounting Accrual | X | MethodOfAccountingAccrual |
| Accountant Compile Or Review | false | AccountantCompileOrReview |
| FS Audited | true | FSAudited |
| Audit Committee | true | AuditCommittee |
| Financial Statement Separate | X | FinancialStatementSeparate |
| Federal Grant Audit Required | false | FederalGrantAuditRequired |
Schedule A IRS990ScheduleA
| Field | Value | IRS element (for citing) |
|---|---|---|
| Publicly Supported Org170b1 Avi | X | PubliclySupportedOrg170b1Avi |
Gifts Grants Contrib Received170 GiftsGrantsContribReceived170
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | 256914242 | CurrentTaxYearMinus4Years |
| Current Tax Year Minus3 Years | 269156149 | CurrentTaxYearMinus3Years |
| Current Tax Year Minus2 Years | 238668944 | CurrentTaxYearMinus2Years |
| Current Tax Year Minus1 Year | 270731343 | CurrentTaxYearMinus1Year |
| Current Tax Year | 283279625 | CurrentTaxYear |
| Total | 1318750303 | Total |
Total170 Total170
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | 256914242 | CurrentTaxYearMinus4Years |
| Current Tax Year Minus3 Years | 269156149 | CurrentTaxYearMinus3Years |
| Current Tax Year Minus2 Years | 238668944 | CurrentTaxYearMinus2Years |
| Current Tax Year Minus1 Year | 270731343 | CurrentTaxYearMinus1Year |
| Current Tax Year | 283279625 | CurrentTaxYear |
| Total | 1318750303 | Total |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Amounts Subst Contributors Total | 83283998 | AmountsSubstContributorsTotal |
| Public Support Total170 | 1235466305 | PublicSupportTotal170 |
Gross Investment Income170 GrossInvestmentIncome170
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | 7451748 | CurrentTaxYearMinus4Years |
| Current Tax Year Minus3 Years | 6950554 | CurrentTaxYearMinus3Years |
| Current Tax Year Minus2 Years | 4962639 | CurrentTaxYearMinus2Years |
| Current Tax Year Minus1 Year | 3145637 | CurrentTaxYearMinus1Year |
| Current Tax Year | 2705046 | CurrentTaxYear |
| Total | 25215624 | Total |
Other Income170 OtherIncome170
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | 1098580 | CurrentTaxYearMinus4Years |
| Current Tax Year Minus3 Years | 2816918 | CurrentTaxYearMinus3Years |
| Current Tax Year Minus2 Years | 1925834 | CurrentTaxYearMinus2Years |
| Current Tax Year Minus1 Year | 1779485 | CurrentTaxYearMinus1Year |
| Current Tax Year | 1502044 | CurrentTaxYear |
| Total | 9122861 | Total |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Support | 1353088788 | TotalSupport |
| Gross Receipts From Admissions Etc | 187378474 | GrossReceiptsFromAdmissionsEtc |
| Public Support Pertcentage170 | 0.91310 | PublicSupportPertcentage170 |
| Public Support Pertcent Prior Year | 0.94640 | PublicSupportPertcentPriorYear |
| Thirty Three Percnt Tests CY170 | X | ThirtyThreePercntTestsCY170 |
Schedule B IRS990ScheduleB
Contributor Info ContributorInfo
| Field | Value | IRS element (for citing) |
|---|---|---|
| Contributor Number | RESTRICTED | ContributorNumber |
Contributor Name Business ContributorNameBusiness
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | RESTRICTED | BusinessNameLine1 |
Contributor Address US ContributorAddressUS
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | RESTRICTED | AddressLine1 |
| Address Line2 | RESTRICTED | AddressLine2 |
| City | RESTRICTED | City |
| State | RESTRICTED | State |
| ZIP Code | RESTRICTED | ZIPCode |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Aggregate Contributions | RESTRICTED | AggregateContributions |
Schedule C IRS990ScheduleC
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form4720 Filed4955 Tax | false | Form4720Filed4955Tax |
| Correction Made | false | CorrectionMade |
| Form1120 Pol Filed | false | Form1120PolFiled |
| Form4720 Filed | false | Form4720Filed |
| Volunteers | true | Volunteers |
| Paid Staff Or Management | true | PaidStaffOrManagement |
| Media Advertisements | false | MediaAdvertisements |
| Mailings Members | false | MailingsMembers |
| Publications Or Broadcast | true | PublicationsOrBroadcast |
| Publications Or Broadcast | $121,269 | PublicationsOrBroadcastAmount |
| Grants Other Organizations | false | GrantsOtherOrganizations |
| Direct Contact Legislators | true | DirectContactLegislators |
| Direct Contact Legislators | $264,232 | DirectContactLegislatorsAmount |
| Rallies Demonstrations | false | RalliesDemonstrations |
| Other Activities | true | OtherActivities |
| Other Activities | $568,404 | OtherActivitiesAmount |
| Total Lobbying Expenditures IIB | 953905 | TotalLobbyingExpendituresIIB |
| Not Described In501c3 | false | NotDescribedIn501c3 |
| Form4720 Filed4912 Tax | false | Form4720Filed4912Tax |
| Substantially All Dues Nondeduct | false | SubstantiallyAllDuesNondeduct |
| Only In House Lobbying | false | OnlyInHouseLobbying |
| Agree To Carryover Prior Year | false | AgreeToCarryoverPriorYear |
Form990 Schedule C Part IV Form990ScheduleCPartIV
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return Reference | SCHEDULE C, PART II-B, LINE 1 | ReturnReference |
| Explanation | LLS IS A MEMBER OF A NUMBER OF COALITIONS INCLUDING RESEARCH AMERICA, ONE VOICE AGAINST CANCER, NATIONAL COALITION FOR CANCER RESEARCH, COALITION FOR THE ADVANCEMENT OF MEDICAL RESEARCH, ALLIANCE FOR A STRONGER FDA, FRIENDS OF CANCER RESEARCH, PATIENT ADVOCATE FOUNDATION, AND THE CENTER FOR ADVANCED HEALTH. LLS PARTNERS WITH A NUMBER OF LOBBYING FIRMS WHO WORK WITH OUR PUBLIC POLICY STAFF TO CARRY OUT OUR LOBBYING OBJECTIVES. | Explanation |
Schedule D IRS990ScheduleD
| Field | Value | IRS element (for citing) |
|---|---|---|
| Disclosed Orgs Legal Control | false | DisclosedOrgsLegalControl |
| Disclosed For Charitable Purposes | false | DisclosedForCharitablePurposes |
| Written Policy Monitoring | false | WrittenPolicyMonitoring |
| Sect170h Requirements Satisfied | false | Sect170hRequirementsSatisfied |
| Collect Used For Public Exhibition | X | CollectUsedForPublicExhibition |
| Solicited Assets For Sale | false | SolicitedAssetsForSale |
| Agent Trustee Etc | false | AgentTrusteeEtc |
| Included On FS | false | IncludedOnFS |
Current Year CurrentYear
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Of Year Balance | 6059994 | BeginningOfYearBalance |
| Investment Earnings Or Losses | 48916 | InvestmentEarningsOrLosses |
| Administrative Expenses | -9992 | AdministrativeExpenses |
| End Of Year Balance | 6000186 | EndOfYearBalance |
Current Year Minus1 Year CurrentYearMinus1Year
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Of Year Balance | 5023902 | BeginningOfYearBalance |
| Contributions | 111064 | Contributions |
| Investment Earnings Or Losses | 938068 | InvestmentEarningsOrLosses |
| Administrative Expenses | -13040 | AdministrativeExpenses |
| End Of Year Balance | 6059994 | EndOfYearBalance |
Current Year Minus2 Years CurrentYearMinus2Years
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Of Year Balance | 4481610 | BeginningOfYearBalance |
| Investment Earnings Or Losses | 563236 | InvestmentEarningsOrLosses |
| Administrative Expenses | -20944 | AdministrativeExpenses |
| End Of Year Balance | 5023902 | EndOfYearBalance |
Current Year Minus3 Years CurrentYearMinus3Years
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Of Year Balance | 5228375 | BeginningOfYearBalance |
| Investment Earnings Or Losses | 730333 | InvestmentEarningsOrLosses |
| Administrative Expenses | -16432 | AdministrativeExpenses |
| End Of Year Balance | 4481610 | EndOfYearBalance |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Permanent Endowment EOY Balance | 0.53000 | PermanentEndowmentEOYBalance |
| Term Endowment EOY Balance | 0.47000 | TermEndowmentEOYBalance |
| Endowments Held By Unrelated Orgs | false | EndowmentsHeldByUnrelatedOrgs |
| Endowments Held By Related Orgs | false | EndowmentsHeldByRelatedOrgs |
| Are Related Orgs Listed Schedule R | false | AreRelatedOrgsListedScheduleR |
Leasehold Improvements LeaseholdImprovements
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | 903003 | OtherCostOrOtherBasis |
| Depreciation | 730475 | Depreciation |
| Book Value | 172528 | BookValue |
Equipment Equipment
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | 15354736 | OtherCostOrOtherBasis |
| Depreciation | 9351645 | Depreciation |
| Book Value | 6003091 | BookValue |
Other Land Buildings OtherLandBuildings
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | 1475590 | OtherCostOrOtherBasis |
| Depreciation | 1010149 | Depreciation |
| Book Value | 465441 | BookValue |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Of Book Value Land Buildings | 6641060 | TotalOfBookValueLandBuildings |
Other Securities OtherSecurities (5 entries)
| DescriptionDescription | Book ValueBookValue | Method Of ValuationMethodOfValuation |
|---|---|---|
| FUND OF HEDGE FUNDS- OPERATING | 36168519 | F |
| LIMITED PARTNERSHIP EQUITIES-OPERATI | 4979287 | F |
| FUND OF HEDGE FUNDS-ENDOWMENT | 1274336 | F |
| 457B PLAN | 1195568 | F |
| LIMITED PARTNERSHIP EQUITIES-ENDOWME | 274396 | F |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Of Book Value Securities | 43892106 | TotalOfBookValueSecurities |
| Total Revenue | 292822993 | TotalRevenue |
| Total Expenses | 292394514 | TotalExpenses |
| Excess Or Deficit For Year | 428479 | ExcessOrDeficitForYear |
| Net Unrealized GL On Investments | -5492300 | NetUnrealizedGLOnInvestments |
| Other | -$1,202,263 | OtherAmount |
| Total Adjustments | -6694563 | TotalAdjustments |
| Excess Or Deficit Per FS | -6266084 | ExcessOrDeficitPerFS |
| Tot Revenue Etc Audited Fincl Stmt | 305088769 | TotRevenueEtcAuditedFinclStmt |
| Net Unrealized Gains Investments | -5492300 | NetUnrealizedGainsInvestments |
| Donated Srvc And Use Of Facilities | 5328250 | DonatedSrvcAndUseOfFacilities |
| Other Revenues | 13028146 | OtherRevenues |
| Revenue Not Rptd F990 | 12864096 | RevenueNotRptdF990 |
| Revenue Subtotal | 292224673 | RevenueSubtotal |
| Investment Expenses Not Included | 598320 | InvestmentExpensesNotIncluded |
| Revenue Not Rptd On Fin Stmt | 598320 | RevenueNotRptdOnFinStmt |
| Total Revenue Per Form990 | 292822993 | TotalRevenuePerForm990 |
| Tot Expenses Etc Audited Fincl Stmt | 311221456 | TotExpensesEtcAuditedFinclStmt |
| Donated Services Use Of Facilities | 5328250 | DonatedServicesUseOfFacilities |
| Other Expenses Included | 14097012 | OtherExpensesIncluded |
| Expenses Not Rptd F990 | 19425262 | ExpensesNotRptdF990 |
| Expenses Subtotal | 291796194 | ExpensesSubtotal |
| Investment Expenses Not Included2 | 598320 | InvestmentExpensesNotIncluded2 |
| Expenses Not Rptd On Fin Stmt | 598320 | ExpensesNotRptdOnFinStmt |
| Total Expenses Per Form990 | 292394514 | TotalExpensesPerForm990 |
Form990 Schedule D Part XIV Form990ScheduleDPartXIV (7 entries)
| IdentifierIdentifier | Return ReferenceReturnReference | ExplanationExplanation |
|---|---|---|
| COLLECTIONS AND RELATION TO EXEMPT PURPOSE | SCHEDULE D, PAGE 2, PART III, LINE 4 | THE LLS COLLECTION IS OF PHOTOGRAPHS WHICH ARE USED FOR PUBLIC EXHIBITION AT FUNDRAISING EVENTS HELD TO SUPPORT LLS'S PROGRAMS. |
| INTENDED USES FOR ENDOWMENT FUNDS | SCHEDULE D, PAGE 2, PART V, LINE 4 | LLS'S ENDOWMENTS ARE INTENDED TO FUND RESEARCH AS WELL AS SUPPORT LLS'S PUBLIC EDUCATION PROGRAMS. |
| LIABILITY UNDER FIN 48 FOOTNOTE | SCHEDULE D, PAGE 3, PART X | LLS RECOGNIZES THE EFFECT OF INCOME TAX POSITIONS ONLY IF THOSE TAX POSITIONS ARE MORE LIKELY THAN NOT TO BE SUSTAINED. INCOME GENERATED FROM ACTIVITIES UNRELATED TO LLS'S EXEMPT PURPOSE IS SUBJECT TO TAX UNDER INTERNAL REVENUE CODE SECTION 511. LLS DID NOT RECOGNIZE ANY UNRELATED BUSINESS INCOME TAX LIABILITY FOR THE YEARS ENDED JUNE 30, 2012 AND 2011. |
| RECONCILIATION OF CHANGES - OTHER | SCHEDULE D, PAGE 4, PART XI, LINE 8 | LLS CANADA REVENUE 12,985,138 LSRP REVENUE 43,009 ROUNDING -1 LLS CANADA EXPENSES -13,424,218 LSRP -1,502 UNCOLLECTABLE MULTI-YEAR PLEDGES -671,292 |
| REVENUE AMOUNTS INCLUDED IN FINANCIALS - OTHER | SCHEDULE D, PAGE 4, PART XII, LINE 2D | LLS CANADA REVENUE 12,985,138 LSRP REVENUE 43,009 ROUNDING -1 |
| EXPENSE AMOUNTS INCLUDED IN FINANCIALS - OTHER | SCHEDULE D, PAGE 4, PART XIII, LINE 2D | LLS CANADA EXPENSES 13,424,218 LSRP 1,502 UNCOLLECTABLE MULTI-YEAR PLEDGES 671,292 |
| SUPPLEMENTAL FINANCIAL INFORMATION | SCHEDULE D, PAGE 4, PART XIV | LLS MAINTAINS A SMALL PHOTOGRAPH COLLECTION FOR PUBLIC EXHIBITION WHICH HAS AN ESTIMATED VALUE BETWEEN 20,000 AND 50,000. AS THIS REPRESENTS A RELATIVELY SMALL PERCENTAGE OF LLS'S ASSETS, IT IS NOT SEPERATELY DISCLOSED IN THE FINANCIAL STATEMENTS OR FOOTNOTES. |
Schedule F IRS990ScheduleF
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | true | GrantRecordsMaintained |
Accts Actvs Out US Table AcctsActvsOutUSTable (5 entries)
| RegionRegion | Number Of OfficesNumberOfOffices | Number Of EmployeesNumberOfEmployees | Type Of Activities ConductedTypeOfActivitiesConducted | Specific Services ProvidedSpecificServicesProvided | Total ExpendituresTotalExpenditures |
|---|---|---|---|---|---|
| EAST ASIA | 2 | 2 | RESEARCH FUNDING | RESEARCH GRANTS | 1450000 |
| EUROPE | 6 | 8 | RESEARCH FUNDING | RESEARCH GRANTS | 1821142 |
| NORTH AMERICA | 12 | 19 | RESEARCH FUNDING | RESEARCH GRANTS | 2641396 |
| MIDDLE EAST | 1 | 1 | RESEARCH FUNDING | RESEARCH GRANTS | 200000 |
| CENTRAL AMERICA & CARIBBEAN | INVESTMENTS | INVESTMENTS |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Subtotal Number Of Offices | 21 | SubtotalNumberOfOffices |
| Subtotal Number Of Employees | 30 | SubtotalNumberOfEmployees |
| Total Number Of Offices | 21 | TotalNumberOfOffices |
| Total Number Of Employees | 30 | TotalNumberOfEmployees |
| Subtotal Amount Spent | 25281986 | SubtotalAmountSpent |
| Total Amount Spent | 25281986 | TotalAmountSpent |
Grants To Orgs Outside US GrantsToOrgsOutsideUS (60 entries)
| RegionRegion | Purpose Of GrantPurposeOfGrant | Amount Of Cash GrantAmountOfCashGrant | Manner Of Cash DisbursementMannerOfCashDisbursement | Method Of ValuationMethodOfValuation |
|---|---|---|---|---|
| EAST ASIA & PACIFIC | RESEARCH GRANT | 1250000 | CHECK | ACCRUAL |
| EUROPE | RESEARCH GRANT | 55000 | CHECK | ACCRUAL |
| EUROPE | RESEARCH GRANT | 65000 | CHECK | ACCRUAL |
| NORTH AMERICA | RESEARCH GRANT | 55000 | CHECK | ACCRUAL |
| NORTH AMERICA | RESEARCH GRANT | 55000 | CHECK | ACCRUAL |
| NORTH AMERICA | RESEARCH GRANT | 200000 | CHECK | ACCRUAL |
| NORTH AMERICA | RESEARCH GRANT | 200000 | CHECK | ACCRUAL |
| NORTH AMERICA | RESEARCH GRANT | 200000 | CHECK | ACCRUAL |
| NORTH AMERICA | RESEARCH GRANT | 55000 | CHECK | ACCRUAL |
| NORTH AMERICA | RESEARCH GRANT | 200000 | CHECK | ACCRUAL |
| NORTH AMERICA | RESEARCH GRANT | 200000 | CHECK | ACCRUAL |
| NORTH AMERICA | RESEARCH GRANT | 200000 | CHECK | ACCRUAL |
| NORTH AMERICA | RESEARCH GRANT | 110000 | CHECK | ACCRUAL |
| NORTH AMERICA | RESEARCH GRANT | 200000 | CHECK | ACCRUAL |
| NORTH AMERICA | RESEARCH GRANT | 200000 | CHECK | ACCRUAL |
| NORTH AMERICA | RESEARCH GRANT | 200000 | CHECK | ACCRUAL |
| NORTH AMERICA | RESEARCH GRANT | 200000 | CHECK | ACCRUAL |
| NORTH AMERICA | RESEARCH GRANT | 200000 | CHECK | ACCRUAL |
| MIDDLE EAST | RESEARCH GRANT | 200000 | CHECK | ACCRUAL |
| EAST ASIA & PACIFIC | RESEARCH GRANT | 200000 | CHECK | ACCRUAL |
| EUROPE | RESEARCH GRANT | 65000 | CHECK | ACCRUAL |
| EUROPE | RESEARCH GRANT | 55000 | CHECK | ACCRUAL |
| EUROPE | RESEARCH GRANT | 1250000 | CHECK | ACCRUAL |
| EUROPE | RESEARCH GRANT | 110000 | CHECK | ACCRUAL |
| EUROPE | RESEARCH GRANT | 200000 | CHECK | ACCRUAL |
| NORTH AMERICA | THERAPY ACCELERATION | 75000 | CHECK | FMV |
| NORTH AMERICA | THERAPY ACCELERATION | 49925 | CHECK | FMV |
| NORTH AMERICA | THERAPY ACCELERATION | 31475 | CHECK | FMV |
| EUROPE | THERAPY ACCELERATION | 21142 | CHECK | FMV |
| NORTH AMERICA | THERAPY ACCELERATION | 9996 | CHECK | FMV |
| EAST ASIA & PACIFIC | RESEARCH GRANT | 1250000 | CHECK | ACCRUAL |
| EUROPE | RESEARCH GRANT | 55000 | CHECK | ACCRUAL |
| EUROPE | RESEARCH GRANT | 65000 | CHECK | ACCRUAL |
| NORTH AMERICA | RESEARCH GRANT | 55000 | CHECK | ACCRUAL |
| NORTH AMERICA | RESEARCH GRANT | 55000 | CHECK | ACCRUAL |
| NORTH AMERICA | RESEARCH GRANT | 200000 | CHECK | ACCRUAL |
| NORTH AMERICA | RESEARCH GRANT | 200000 | CHECK | ACCRUAL |
| NORTH AMERICA | RESEARCH GRANT | 200000 | CHECK | ACCRUAL |
| NORTH AMERICA | RESEARCH GRANT | 55000 | CHECK | ACCRUAL |
| NORTH AMERICA | RESEARCH GRANT | 200000 | CHECK | ACCRUAL |
| NORTH AMERICA | RESEARCH GRANT | 200000 | CHECK | ACCRUAL |
| NORTH AMERICA | RESEARCH GRANT | 200000 | CHECK | ACCRUAL |
| NORTH AMERICA | RESEARCH GRANT | 110000 | CHECK | ACCRUAL |
| NORTH AMERICA | RESEARCH GRANT | 200000 | CHECK | ACCRUAL |
| NORTH AMERICA | RESEARCH GRANT | 200000 | CHECK | ACCRUAL |
| NORTH AMERICA | RESEARCH GRANT | 200000 | CHECK | ACCRUAL |
| NORTH AMERICA | RESEARCH GRANT | 200000 | CHECK | ACCRUAL |
| NORTH AMERICA | RESEARCH GRANT | 200000 | CHECK | ACCRUAL |
| MIDDLE EAST | RESEARCH GRANT | 200000 | CHECK | ACCRUAL |
| EAST ASIA & PACIFIC | RESEARCH GRANT | 200000 | CHECK | ACCRUAL |
| EUROPE | RESEARCH GRANT | 65000 | CHECK | ACCRUAL |
| EUROPE | RESEARCH GRANT | 55000 | CHECK | ACCRUAL |
| EUROPE | RESEARCH GRANT | 1250000 | CHECK | ACCRUAL |
| EUROPE | RESEARCH GRANT | 110000 | CHECK | ACCRUAL |
| EUROPE | RESEARCH GRANT | 200000 | CHECK | ACCRUAL |
| NORTH AMERICA | THERAPY ACCELERATION | 75000 | CHECK | FMV |
| NORTH AMERICA | THERAPY ACCELERATION | 49925 | CHECK | FMV |
| NORTH AMERICA | THERAPY ACCELERATION | 31475 | CHECK | FMV |
| EUROPE | THERAPY ACCELERATION | 21142 | CHECK | FMV |
| NORTH AMERICA | THERAPY ACCELERATION | 9996 | CHECK | FMV |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Number Of Other Orgs | 21 | TotalNumberOfOtherOrgs |
Form990 Schedule F Part V Form990ScheduleFPartV (2 entries)
| IdentifierIdentifier | Return ReferenceReturnReference | ExplanationExplanation |
|---|---|---|
| PROCEDURES FOR MONITORING THE USE OF GRANT FUNDS OUTSIDE THE UNITED STATES | SCHEDULE F, PAGE 1, PART I, LINE 2 | FIDUCIARY RESPONSIBILITY AND TRANSPARENCY TO OUR DONORS IS A HIGH PRIORITY. THE LEUKEMIA & LYMPHOMA SOCIETY (LLS) PLACES CONSIDERABLE EMPHASIS ON THE OVERSIGHT OF GRANT SPENDING. TO ACCOMPLISH THIS WE REQUIRE THE SUBMISSION OF ANNUAL FINANCIAL REPORTS FOR EACH OF OUR ACTIVE GRANTS. THE REPORT MUST BE SIGNED BY THE FINANCIAL OFFICER AND/OR THE DESIGNATED OFFICIAL OF THE INSTITUTION HOSTING THE AWARD. AT THE END OF THE GRANT, WE REQUIRE A FINAL FINANCIAL REPORT THAT PROVIDES AN OVERVIEW OF ALL SPENDING THROUGH THE DURATION OF THE AWARD. WE REQUIRE SPECIFIC ACCOUNTING OF SPENDING ON PERSONNEL, CONSULTANTS,EQUIPMENT PURCHASES, SUPPLIES, TRAVEL, PATIENT CARE COSTS, ANIMAL CARE COSTS, AND ANY OTHER EXPENSE A GRANTEE MAY INCUR. WE HAVE SPECIFIC INSTRUCTIONS AND DOLLAR AMOUNT LIMITATIONS SET FOR MANY OF THESE CATEGORIES DEPENDING ON THE AWARD TYPE. FINANCIAL REPORTS ARE REVIEWED FOR NUMERICAL ACCURACY, ADHERENCE TO OUR GUIDELINES, AND FOR THE VERIFICATION OF APPROVAL FROM THE INSTITUTION'S FINANCIAL OFFICER. IF THE GRANTEE DOES NOT SUBMIT AN ANNUAL FINANCIAL REPORT BY THE DUE DATE OUTLINED IN THEIR CONTRACT, FUNDING IS SUSPENDED UNTIL LLS RECEIVES AND APPROVES THE DELINQUENT REPORT. |
| EAST ASIA 1,450,000 0 EUROPE 1,821,142 0 NORTH AMERICA 2,641,396 0 MIDDLE EAST 200,000 0 CENTRAL AMERICA & CARIBBEAN 0 19,169,448 |
Schedule G IRS990ScheduleG
| Field | Value | IRS element (for citing) |
|---|---|---|
| Mail Solicitations | X | MailSolicitations |
| Email Solicitations | X | EmailSolicitations |
| Phone Solicitations | X | PhoneSolicitations |
| In Person Solicitations | X | InPersonSolicitations |
| Solicitation Of Non Govt Grants | X | SolicitationOfNonGovtGrants |
| Solicitation Of Govt Grants | X | SolicitationOfGovtGrants |
| Special Fundraising Events | X | SpecialFundraisingEvents |
| Agreement Ref Fundraising | true | AgreementRefFundraising |
Fundraiser Activity Information FundraiserActivityInformation (8 entries)
| Address Line1AddressUS/AddressLine1 | CityAddressUS/City | StateAddressUS/State | ZIP CodeAddressUS/ZIPCode | ActivityActivity | Fundraiser Control Of FundsFundraiserControlOfFunds | Amount Retained By ContractorAmountRetainedByContractor | Net To OrganizationNetToOrganization |
|---|---|---|---|---|---|---|---|
| PARADYZ MATERA | |||||||
| 5 HANOVER SQUARE 6TH FLOOR | NEW YORK | NY | 10004 | DIRECT MAI | false | 2641112 | -2641112 |
| DIRECT PRINT COMMUNICATIONS | |||||||
| 201 EAST SANDPOINTE SUITE 400 | SANTA ANA | CA | 92707 | DIRECT MAI | false | 2324784 | -2324784 |
| INFOCISION | |||||||
| 325 SPRINSIDE DRIVE | AKRON | OH | 44333 | TELEMARKET | false | 2010620 | -2010620 |
| MSP | |||||||
| PO BOX 641114 | PITTSBURGH | PA | 15264 | DIRECT MAI | false | 1954908 | -1954908 |
| THOMPSON HABIB & DENISON | |||||||
| 80 HAYDEN AVENUE SUITE 300 | LEXINGTON | MA | 02421 | DIRECT MAI | false | 664097 | -664097 |
| HAINES & COMPANY | |||||||
| 8050 FREEDOM AVENUE | CANTON | OH | 44720 | TELEMARKET | false | 261594 | -261594 |
| BLACKBAUD | |||||||
| 1800 DIAGONAL ROAD SUITE 400 | ALEXANDRIA | VA | 22314 | DIRECT MAI | false | 191860 | -191860 |
| DONOR CARE CENTER INC | |||||||
| 4345 STRAUSSSER ST NW | NOTH CANTON | OH | 44720 | TELEMARKET | false | 126428 | -126428 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Retained By Contractors | 10175403 | TotalRetainedByContractors |
| All States | All States | AllStates |
Events Information EventsInformation
| Field | Value | IRS element (for citing) |
|---|---|---|
| Name Of Event1 | NIKE WOMENS MAR | NameOfEvent1 |
| Gross Receipts Event1 | 10133172 | GrossReceiptsEvent1 |
| Charitable Contributions Event1 | 7218103 | CharitableContributionsEvent1 |
| Gross Revenue Event1 | 2915069 | GrossRevenueEvent1 |
| Other Direct Expenses Event1 | 2915069 | OtherDirectExpensesEvent1 |
| Name Of Event2 | ROCK N ROLL MAR | NameOfEvent2 |
| Gross Receipts Event2 | 6943611 | GrossReceiptsEvent2 |
| Charitable Contributions Event2 | 4823819 | CharitableContributionsEvent2 |
| Gross Revenue Event2 | 2119792 | GrossRevenueEvent2 |
| Other Direct Expenses Event2 | 2119792 | OtherDirectExpensesEvent2 |
| Total Number Of Other Events | 1051 | TotalNumberOfOtherEvents |
| Gross Receipts Other Events | 177025766 | GrossReceiptsOtherEvents |
| Charitable Contrib Other Events | 145192689 | CharitableContribOtherEvents |
| Gross Revenue Other Events | 31833077 | GrossRevenueOtherEvents |
| Other Direct Expenses Other Events | 31833077 | OtherDirectExpensesOtherEvents |
| Gross Receipts Total | 194102549 | GrossReceiptsTotal |
| Charitable Contributions Total | 157234611 | CharitableContributionsTotal |
| Gross Revenue Total Events | 36867938 | GrossRevenueTotalEvents |
| Other Direct Expenses Total Events | 36867938 | OtherDirectExpensesTotalEvents |
| Direct Expense Summary Events | 36867938 | DirectExpenseSummaryEvents |
Gaming Information GamingInformation
| Field | Value | IRS element (for citing) |
|---|---|---|
| Volunteer Labor Bingo | false | VolunteerLaborBingo |
| Volunteer Labor Pull Tabs | false | VolunteerLaborPullTabs |
| Gross Revenue Other Gaming | 940518 | GrossRevenueOtherGaming |
| Cash Prizes Other Gaming | 5208 | CashPrizesOtherGaming |
| Non Cash Prizes Other Gaming | 290575 | NonCashPrizesOtherGaming |
| Rent Facility Costs Other Gaming | 20511 | RentFacilityCostsOtherGaming |
| Other Direct Expenses Other Gaming | 16672 | OtherDirectExpensesOtherGaming |
| Volunteer Labor Other Gaming | true | VolunteerLaborOtherGaming |
| Volunteer Labor Prcnt Other Gaming | 0.12000 | VolunteerLaborPrcntOtherGaming |
| Gross Revenue Total Gaming | 940518 | GrossRevenueTotalGaming |
| Cash Prizes Total Gaming | 5208 | CashPrizesTotalGaming |
| Non Cash Prizes Total Gaming | 290575 | NonCashPrizesTotalGaming |
| Rent Facility Costs Total Gaming | 20511 | RentFacilityCostsTotalGaming |
| Other Direct Expenses Total Gaming | 16672 | OtherDirectExpensesTotalGaming |
| Direct Expense Summary Gaming | 332966 | DirectExpenseSummaryGaming |
| Net Gaming Income Summary | 607552 | NetGamingIncomeSummary |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Licensed | true | Licensed |
| License Suspended Etc | false | LicenseSuspendedEtc |
| Gaming With Nonmembers | false | GamingWithNonmembers |
| Member Of Other Entity | false | MemberOfOtherEntity |
| Percentage Of Gaming Own Facility | 0.01000 | PercentageOfGamingOwnFacility |
| Percentage Of Gaming Othr Facility | 0.99000 | PercentageOfGamingOthrFacility |
| Name Of Gaming Rec Keeper Person | JAMES T NANGLE | NameOfGamingRecKeeperPerson |
Address Of Gaming Rec Keeper US AddressOfGamingRecKeeperUS
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 1311 MAMARONECK AVENUE | AddressLine1 |
| City | WHITE PLAINS | City |
| State | NY | State |
| ZIP Code | 10605 | ZIPCode |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Contract With3rd Party For Gam Rev | false | ContractWith3rdPartyForGamRev |
| Charitable Distrib Required | false | CharitableDistribRequired |
Form990 Schedule G Part IV Form990ScheduleGPartIV
| Field | Value | IRS element (for citing) |
|---|---|---|
| Explanation | SCHEDULE G PART I LINE 2B LLS USED INFOCISON HAINES COMPANY DONOR CARE CENTER INC AND THOMPSON HABIB DENISON FOR ITS NATIONAL COMMUNITY CAMPAIGN AND DIRECT MAIL PROGRAMS THESE PROGRAMS GENERATED GROSS RECEIPTS OF 26431738 DURING FISCAL YEAR 2012LLS USED DIRECT PRINT COMMUNICATIONS PARADYZ MATERA AND BLACKBAUD FOR ALL OF ITS OTHER FUNDRAISING EVENTS DURING FISCAL YEAR 2012 SCHEDULE G PART III LINE 9STATES WITH GAMING OPERATIONS ARIZONA CALIFORNIA CONNECTICUT DISTRICT OF COLUMBIA FLORIDA GEORGIA ILLINOIS IOWA KANSAS LOUISIANA MASSACHUSETTS MARYLAND MICHIGAN MINNESOTA MISSISSIPPI NEVADA NEW JERSEY NEW YORK OHIO OREGON PENNSYLVANIA RHODE ISLAND TEXAS VIRGINIA WASHINGTON WISCONSIN | Explanation |
Schedule I IRS990ScheduleI
| Field | Value | IRS element (for citing) |
|---|---|---|
| Records Maintained | true | RecordsMaintained |
Recipient Table RecipientTable (307 entries)
| Address Line1AddressUS/AddressLine1 | CityAddressUS/City | StateAddressUS/State | ZIP CodeAddressUS/ZIPCode | EIN Of RecipientEINOfRecipient | IRC SectionIRCSection | Amount Of Cash GrantAmountOfCashGrant | Method Of ValuationMethodOfValuation | Purpose Of GrantPurposeOfGrant |
|---|---|---|---|---|---|---|---|---|
| ALBERT EINSTEIN COLLEGE OF MEDICINE | ||||||||
| 1300 MORRIS PARK AVE | BRONX | NY | 10461 | 131624225 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| ALBERT EINSTEIN COLLEGE OF MEDICINE | ||||||||
| 1300 MORRIS PARK AVE | BRONX | NY | 10461 | 131624225 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| ALBERT EINSTEIN COLLEGE OF MEDICINE | ||||||||
| 1300 MORRIS PARK AVE | BRONX | NY | 10461 | 131624225 | 3 | 110000 | ACCRUAL | RESEARCH GRANT |
| BAYLOR COLLEGE OF MEDICINE | ||||||||
| 1 BAYLOR PLAZA | HOUSTON | TX | 77002 | 741613878 | 3 | 65000 | ACCRUAL | RESEARCH GRANT |
| BAYLOR COLLEGE OF MEDICINE | ||||||||
| 1 BAYLOR PLAZA | HOUSTON | TX | 77002 | 741613878 | 3 | 1250000 | ACCRUAL | RESEARCH GRANT |
| BAYLOR COLLEGE OF MEDICINE | ||||||||
| 1 BAYLOR PLAZA | HOUSTON | TX | 77002 | 741613878 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| BAYLOR COLLEGE OF MEDICINE | ||||||||
| 1 BAYLOR PLAZA | HOUSTON | TX | 77002 | 741613878 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| BECKMAN RESEARCH INSTITUTE OF THE C | ||||||||
| 1500 EAST DUARTE ROAD | DUARTE | CA | 91010 | 953432210 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| BECKMAN RESEARCH INSTITUTE OF THE C | ||||||||
| 1500 EAST DUARTE ROAD | DUARTE | CA | 91010 | 953432210 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| BECKMAN RESEARCH INSTITUTE OF THE C | ||||||||
| 1500 EAST DUARTE ROAD | DUARTE | CA | 91010 | 953432210 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| BETH ISRAEL DEACONESS MEDICAL CENTE | ||||||||
| 330 BROOKLINE AVENUE | BOSTON | MA | 02108 | 042103881 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| BETH ISRAEL DEACONESS MEDICAL CENTE | ||||||||
| 330 BROOKLINE AVENUE | BOSTON | MA | 02108 | 042103881 | 3 | 55000 | ACCRUAL | RESEARCH GRANT |
| BETH ISRAEL DEACONESS MEDICAL CENTE | ||||||||
| 330 BROOKLINE AVENUE | BOSTON | MA | 02108 | 042103881 | 3 | 65000 | ACCRUAL | RESEARCH GRANT |
| BRANDEIS UNIVERSITY | ||||||||
| 415 SOUTH STREET | WALTHAM | MA | 02453 | 042103552 | 3 | 55000 | ACCRUAL | RESEARCH GRANT |
| BRIGHAM AND WOMEN'S HOSPITAL INC | ||||||||
| 1 BLACKFAN CIRCLE | BOSTON | MA | 02115 | 042312909 | 3 | 110000 | ACCRUAL | RESEARCH GRANT |
| BRIGHAM AND WOMEN'S HOSPITAL INC | ||||||||
| 1 JIMMY FUND WAYSMITH BUILDING ROO | BOSTON | MA | 02115 | 042312909 | 3 | 110000 | ACCRUAL | RESEARCH GRANT |
| BRIGHAM AND WOMEN'S HOSPITAL INC | ||||||||
| 75 FRANCIS STREET | BOSTON | MA | 02115 | 042312909 | 3 | 65000 | ACCRUAL | RESEARCH GRANT |
| BRIGHAM AND WOMEN'S HOSPITAL INC | ||||||||
| 75 FRANCIS STREET | BOSTON | MA | 02115 | 042312909 | 3 | 1250000 | ACCRUAL | RESEARCH GRANT |
| CHILDRENS HOSPITAL LOS ANGELES | ||||||||
| 4650 SUNSET BLVD | LOS ANGELES | CA | 90001 | 951690977 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| CHILDRENS HOSPITAL LOS ANGELES | ||||||||
| 513 PARNASSUS AVENUE | SAN FRANCISCO | CA | 94143 | 951690977 | 3 | 110000 | ACCRUAL | RESEARCH GRANT |
| CHILDRENS HOSPITAL LOS ANGELES | ||||||||
| 513 PARNASSUS AVENUE | SAN FRANCISCO | CA | 94143 | 951690977 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| CHILDRENS HOSPITAL MEDICAL CENTER-C | ||||||||
| 7013 3333 BURNET AVENUE | CINCINNATI | OH | 45202 | 310833936 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| CHILDRENS HOSPITAL MEDICAL CENTER-C | ||||||||
| 7013 3333 BURNET AVENUE | CINCINNATI | OH | 45202 | 310833936 | 3 | 110000 | ACCRUAL | RESEARCH GRANT |
| CHILDRENS HOSPITAL MEDICAL CENTER-C | ||||||||
| 7013 3333 BURNET AVENUE | CINCINNATI | OH | 45202 | 310833936 | 3 | 110000 | ACCRUAL | RESEARCH GRANT |
| CHILDRENS HOSPITAL MEDICAL CENTER-C | ||||||||
| 7013 3333 BURNET AVENUE | CINCINNATI | OH | 45202 | 310833936 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| CHILDRENS HOSPITAL OF BOSTON | ||||||||
| 300 LONGWOOD AVENUE | BOSTON | MA | 02108 | 042774441 | 3 | 110000 | ACCRUAL | RESEARCH GRANT |
| CLEVELAND CLINIC FOUNDATION | ||||||||
| 9500 EUCLID AVENUE | CLEVELAND | OH | 44195 | 340714553 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| COLUMBIA UNIVERSITY MEDICAL CENTER | ||||||||
| 1150 ST NICHOLAS AVENUE | NEW YORK | NY | 10001 | 135598093 | 3 | 1250000 | ACCRUAL | RESEARCH GRANT |
| COLUMBIA UNIVERSITY MEDICAL CENTER | ||||||||
| 1150 ST NICHOLAS AVENUE | NEW YORK | NY | 10001 | 135598093 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| COLUMBIA UNIVERSITY MEDICAL CENTER | ||||||||
| 1150 ST NICHOLAS AVENUE | NEW YORK | NY | 10001 | 135598093 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| COLUMBIA UNIVERSITY MEDICAL CENTER | ||||||||
| 1150 ST NICHOLAS AVENUE | NEW YORK | NY | 10001 | 135598093 | 3 | 55000 | ACCRUAL | RESEARCH GRANT |
| COLUMBIA UNIVERSITY MEDICAL CENTER | ||||||||
| 1150 ST NICHOLAS AVENUE | NEW YORK | NY | 10001 | 135598093 | 3 | 55000 | ACCRUAL | RESEARCH GRANT |
| COLUMBIA UNIVERSITY MEDICAL CENTER | ||||||||
| 1150 ST NICHOLAS AVENUE | NEW YORK | NY | 10001 | 135598093 | 3 | 110000 | ACCRUAL | RESEARCH GRANT |
| COLUMBIA UNIVERSITY MEDICAL CENTER | ||||||||
| 1150 ST NICHOLAS AVENUE | NEW YORK | NY | 10001 | 135598093 | 3 | 55000 | ACCRUAL | RESEARCH GRANT |
| CORNELL UNIVERSITY | ||||||||
| 1300 YORK AVENUEROOM C-338 | NEW YORK | NY | 10065 | 150532082 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| DANA FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVEN | BOSTON | MA | 02115 | 042263040 | 3 | 55000 | ACCRUAL | RESEARCH GRANT |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 44 BINNEY STREET | BOSTON | MA | 02108 | 042263040 | 3 | 110000 | ACCRUAL | RESEARCH GRANT |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 44 BINNEY STREET | BOSTON | MA | 02108 | 042263040 | 3 | 55000 | ACCRUAL | RESEARCH GRANT |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 44 BINNEY STREET | BOSTON | MA | 02108 | 042263040 | 3 | 110000 | ACCRUAL | RESEARCH GRANT |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 44 BINNEY STREET | BOSTON | MA | 02108 | 042263040 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 44 BINNEY STREET | BOSTON | MA | 02108 | 042263040 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 44 BINNEY STREET | BOSTON | MA | 02108 | 042263040 | 3 | 65000 | ACCRUAL | RESEARCH GRANT |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 44 BINNEY STREET | BOSTON | MA | 02108 | 042263040 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 44 BINNEY STREET | BOSTON | MA | 02108 | 042263040 | 3 | 100000 | ACCRUAL | RESEARCH GRANT |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 44 BINNEY STREET | BOSTON | MA | 02108 | 042263040 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 44 BINNEY STREET | BOSTON | MA | 02108 | 042263040 | 3 | 55000 | ACCRUAL | RESEARCH GRANT |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 44 BINNEY STREET | BOSTON | MA | 02108 | 042263040 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 44 BINNEY STREET | BOSTON | MA | 02108 | 042263040 | 3 | 55000 | ACCRUAL | RESEARCH GRANT |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 44 BINNEY STREET | BOSTON | MA | 02108 | 042263040 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 44 BINNEY STREET | BOSTON | MA | 02108 | 042263040 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 44 BINNEY STREET | BOSTON | MA | 02108 | 042263040 | 3 | 65000 | ACCRUAL | RESEARCH GRANT |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 44 BINNEY STREET | BOSTON | MA | 02108 | 042263040 | 3 | 110000 | ACCRUAL | RESEARCH GRANT |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 44 BINNEY STREET | BOSTON | MA | 02108 | 042263040 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 44 BINNEY STREET | BOSTON | MA | 02108 | 042263040 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 44 BINNEY STREET | BOSTON | MA | 02108 | 042263040 | 3 | 55000 | ACCRUAL | RESEARCH GRANT |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 44 BINNEY STREET | BOSTON | MA | 02108 | 042263040 | 3 | 55000 | ACCRUAL | RESEARCH GRANT |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 44 BINNEY STREET | BOSTON | MA | 02108 | 042263040 | 3 | 65000 | ACCRUAL | RESEARCH GRANT |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 44 BINNEY STREET | BOSTON | MA | 02108 | 042263040 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 44 BINNEY STREET | BOSTON | MA | 02108 | 042263040 | 3 | 55000 | ACCRUAL | RESEARCH GRANT |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 44 BINNEY STREET | BOSTON | MA | 02108 | 042263040 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 44 BINNEY STREET | BOSTON | MA | 02108 | 042263040 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 44 BINNEY STREET | BOSTON | MA | 02108 | 042263040 | 3 | 55000 | ACCRUAL | RESEARCH GRANT |
| DREXEL UNIVERSITY | ||||||||
| 497 245 N 15TH STREET | PHILADELPHIA | PA | 19102 | 231352630 | 3 | 110000 | ACCRUAL | RESEARCH GRANT |
| DUKE UNIVERSITY MEDICAL CENTER | ||||||||
| 3813 BOX RESEARCH DRIVE | DURHAM | NC | 27710 | 560532129 | 3 | 55000 | ACCRUAL | RESEARCH GRANT |
| DUKE UNIVERSITY MEDICAL CENTER | ||||||||
| 3813 BOX RESEARCH DRIVE | DURHAM | NC | 27710 | 560532129 | 3 | 110000 | ACCRUAL | RESEARCH GRANT |
| EMORY UNIVERSITY | ||||||||
| 1599 CLIFTON ROAD NE | ATLANTA | GA | 30303 | 580566256 | 3 | 110000 | ACCRUAL | RESEARCH GRANT |
| FRED HUTCHINSON CANCER RESEARCH CEN | ||||||||
| 1100 FAIRVIEW AVENUE NORTH | SEATTLE | WA | 98109 | 237156071 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| FRED HUTCHINSON CANCER RESEARCH CEN | ||||||||
| 1100 FAIRVIEW AVENUE NORTH | SEATTLE | WA | 98109 | 237156071 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| FRED HUTCHINSON CANCER RESEARCH CEN | ||||||||
| 1100 FAIRVIEW AVENUE NORTH | SEATTLE | WA | 98109 | 237156071 | 3 | 55000 | ACCRUAL | RESEARCH GRANT |
| FRED HUTCHINSON CANCER RESEARCH CEN | ||||||||
| 1100 FAIRVIEW AVENUE NORTH | SEATTLE | WA | 98109 | 237156071 | 3 | 65000 | ACCRUAL | RESEARCH GRANT |
| HARVARD MEDICAL SCHOOL | ||||||||
| 1 BLACKFAN CIRCLE | BOSTON | MA | 02108 | 530199180 | 3 | 65000 | ACCRUAL | RESEARCH GRANT |
| HARVARD MEDICAL SCHOOL | ||||||||
| 1 BLACKFAN CIRCLE | BOSTON | MA | 02108 | 530199180 | 3 | 55000 | ACCRUAL | RESEARCH GRANT |
| HARVARD MEDICAL SCHOOL | ||||||||
| 1 BLACKFAN CIRCLE | BOSTON | MA | 02108 | 530199180 | 3 | 65000 | ACCRUAL | RESEARCH GRANT |
| HEALTH RESEARCH INCORPORATED ROSWE | ||||||||
| 1 ELM CARLTON STREETS | BUFFALO | NY | 14201 | 141402155 | 110000 | ACCRUAL | RESEARCH GRANT | |
| INDIANA UNIVERSITY | ||||||||
| 1044 W WALNUT STREET | INDIANAPOLIS | IN | 46201 | 356018940 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| JOAN & SANFORD I WEILL MEDICAL COL | ||||||||
| 435 EAST 70TH STREET | NEW YORK | NY | 10001 | 133376695 | 3 | 55000 | ACCRUAL | RESEARCH GRANT |
| JOAN & SANFORD I WEILL MEDICAL COL | ||||||||
| 435 EAST 70TH STREET | NEW YORK | NY | 10001 | 133376695 | 3 | 65000 | ACCRUAL | RESEARCH GRANT |
| JOAN & SANFORD I WEILL MEDICAL COL | ||||||||
| 435 EAST 70TH STREET | NEW YORK | NY | 10001 | 133376695 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| JOAN & SANFORD I WEILL MEDICAL COL | ||||||||
| 435 EAST 70TH STREET | NEW YORK | NY | 10001 | 133376695 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| JOAN & SANFORD I WEILL MEDICAL COL | ||||||||
| 435 EAST 70TH STREET | NEW YORK | NY | 10001 | 133376695 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| JOAN & SANFORD I WEILL MEDICAL COL | ||||||||
| 435 EAST 70TH STREET | NEW YORK | NY | 10001 | 133376695 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| JOAN & SANFORD I WEILL MEDICAL COL | ||||||||
| 435 EAST 70TH STREET | NEW YORK | NY | 10001 | 133376695 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| JOAN & SANFORD I WEILL MEDICAL COL | ||||||||
| 435 EAST 70TH STREET | NEW YORK | NY | 10001 | 133376695 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| JOAN & SANFORD I WEILL MEDICAL COL | ||||||||
| 435 EAST 70TH STREET | NEW YORK | NY | 10001 | 133376695 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| JOHNS HOPKINS UNIVERSITY | ||||||||
| 1101 EAST 33RD STREET | BALTIMORE | MD | 21201 | 520595110 | 3 | 110000 | ACCRUAL | RESEARCH GRANT |
| JOHNS HOPKINS UNIVERSITY | ||||||||
| 1101 EAST 33RD STREET | BALTIMORE | MD | 21201 | 520595110 | 3 | 110000 | ACCRUAL | RESEARCH GRANT |
| JOHNS HOPKINS UNIVERSITY SCHOOL OF | ||||||||
| 725 NORTH WOLFE STREET | BALTIMORE | MD | 21201 | 520595110 | 3 | 55000 | ACCRUAL | RESEARCH GRANT |
| JOHNS HOPKINS UNIVERSITY SCHOOL OF | ||||||||
| 725 NORTH WOLFE STREET | BALTIMORE | MD | 21201 | 520595110 | 3 | 110000 | ACCRUAL | RESEARCH GRANT |
| JOHNS HOPKINS UNIVERSITY SCHOOL OF | ||||||||
| 725 NORTH WOLFE STREET | BALTIMORE | MD | 21201 | 520595110 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| JOHNS HOPKINS UNIVERSITY SCHOOL OF | ||||||||
| 725 NORTH WOLFE STREET | BALTIMORE | MD | 21201 | 520595110 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| JOHNS HOPKINS UNIVERSITY SCHOOL OF | ||||||||
| 725 NORTH WOLFE STREET | BALTIMORE | MD | 21201 | 520595110 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| JOHNS HOPKINS UNIVERSITY SCHOOL OF | ||||||||
| 725 NORTH WOLFE STREET | BALTIMORE | MD | 21201 | 520595110 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| JOHNS HOPKINS UNIVERSITY SCHOOL OF | ||||||||
| 725 NORTH WOLFE STREET | BALTIMORE | MD | 21201 | 520595110 | 3 | 110000 | ACCRUAL | RESEARCH GRANT |
| JOHNS HOPKINS UNIVERSITY SCHOOL OF | ||||||||
| 725 NORTH WOLFE STREET | BALTIMORE | MD | 21201 | 520595110 | 3 | 65000 | ACCRUAL | RESEARCH GRANT |
| LA JOLLA INSTITUTE FOR ALLERGY & IM | ||||||||
| 9420 ATHENA CIRCLE | LA JOLLA | CA | 92037 | 330328688 | 3 | 65000 | ACCRUAL | RESEARCH GRANT |
| LA JOLLA INSTITUTE FOR ALLERGY & IM | ||||||||
| 9420 ATHENA CIRCLE | LA JOLLA | CA | 92037 | 330328688 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| LA JOLLA INSTITUTE FOR ALLERGY AND | ||||||||
| 9420 ATHENA CIRCLE | LA JOLLA | CA | 92037 | 330328688 | 3 | 55000 | ACCRUAL | RESEARCH GRANT |
| LA JOLLA INSTITUTE FOR ALLERGY AND | ||||||||
| 9420 ATHENA CIRCLE | LA JOLLA | CA | 92037 | 330328688 | 3 | 65000 | ACCRUAL | RESEARCH GRANT |
| LUDWIG INSTITUTE FOR CANCER RESEARC | ||||||||
| 9500 GILMAN DRIVECMM-EAST | LA JOLLA | CA | 92093 | 237121131 | 3 | 65000 | ACCRUAL | RESEARCH GRANT |
| MASSACHUSETTS GENERAL HOSPITAL (THE | ||||||||
| 50 STANIFORD STREET | BOSTON | MA | 02108 | 041564655 | 3 | 55000 | ACCRUAL | RESEARCH GRANT |
| MASSACHUSETTS GENERAL HOSPITAL (THE | ||||||||
| 50 STANIFORD STREET | BOSTON | MA | 02108 | 041564655 | 3 | 110000 | ACCRUAL | RESEARCH GRANT |
| MASSACHUSETTS GENERAL HOSPITAL (THE | ||||||||
| 50 STANIFORD STREET | BOSTON | MA | 02108 | 041564655 | 3 | 65000 | ACCRUAL | RESEARCH GRANT |
| MASSACHUSETTS GENERAL HOSPITAL (THE | ||||||||
| 50 STANIFORD STREET | BOSTON | MA | 02108 | 041564655 | 3 | 55000 | ACCRUAL | RESEARCH GRANT |
| MASSACHUSETTS GENERAL HOSPITAL (THE | ||||||||
| 50 STANIFORD STREET | BOSTON | MA | 02108 | 041564655 | 3 | 55000 | ACCRUAL | RESEARCH GRANT |
| MASSACHUSETTS GENERAL HOSPITAL (THE | ||||||||
| 50 STANIFORD STREET | BOSTON | MA | 02108 | 041564655 | 3 | 110000 | ACCRUAL | RESEARCH GRANT |
| MASSACHUSETTS INSTITUTE OF TECHNOLO | ||||||||
| 77 MASSACHUSETTS AVENUE | CAMBRIDGE | MA | 02138 | 042103594 | 3 | 55000 | ACCRUAL | RESEARCH GRANT |
| MASSACHUSETTS INSTITUTE OF TECHNOLO | ||||||||
| 77 MASSACHUSETTS AVENUE | CAMBRIDGE | MA | 02138 | 042103594 | 3 | 55000 | ACCRUAL | RESEARCH GRANT |
| MAYO CLINIC ARIZONA DBA MAYO CLI | ||||||||
| 13400 EAST SHEA BOULEVARD | SCOTTSDALE | AZ | 85250 | 860800150 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| MAYO CLINIC ARIZONA DBA MAYO CLI | ||||||||
| 13400 EAST SHEA BOULEVARD | SCOTTSDALE | AZ | 85250 | 860800150 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| MAYO CLINIC ARIZONA DBA MAYO CLI | ||||||||
| 13400 EAST SHEA BOULEVARD | SCOTTSDALE | AZ | 85250 | 860800150 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| MAYO CLINIC JACKSONVILLE | ||||||||
| 4500 SAN PABLO RD | JACKSONVILLE | FL | 32224 | 593337028 | 3 | 100000 | ACCRUAL | RESEARCH GRANT |
| MAYO CLINIC ROCHESTER | ||||||||
| 200 FIRST STREET SW | ROCHESTER | MN | 55905 | 416011702 | 3 | 110000 | ACCRUAL | RESEARCH GRANT |
| MAYO CLINIC ROCHESTER | ||||||||
| 200 FIRST STREET SW | ROCHESTER | MN | 55905 | 411506440 | 3 | 100000 | ACCRUAL | RESEARCH GRANT |
| MAYO CLINIC ROCHESTER | ||||||||
| 200 FIRST STREET SW | ROCHESTER | MN | 55905 | 416011702 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| MAYO CLINIC ROCHESTER | ||||||||
| 200 FIRST STREET SW | ROCHESTER | MN | 55905 | 416011702 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| MAYO CLINIC ROCHESTER | ||||||||
| 200 FIRST STREET SW | ROCHESTER | MN | 55905 | 416011702 | 3 | 110000 | ACCRUAL | RESEARCH GRANT |
| MEDICAL COLLEGE OF WISCONSIN | ||||||||
| 8701 WATERTOWN PLANK ROAD | MILWAUKEE | WI | 53226 | 390806261 | 3 | 110000 | ACCRUAL | RESEARCH GRANT |
| MEMORIAL SLOAN KETTERING CANCER CEN | ||||||||
| 633 THIRD AVENUE | NEW YORK | NY | 10001 | 912154267 | 3 | 55000 | ACCRUAL | RESEARCH GRANT |
| MEMORIAL SLOAN-KETTERING CANCER CEN | ||||||||
| 633 THIRD AVENUE | NEW YORK | NY | 10001 | 912154267 | 3 | 55000 | ACCRUAL | RESEARCH GRANT |
| MEMORIAL SLOAN-KETTERING CANCER CEN | ||||||||
| 633 THIRD AVENUE | NEW YORK | NY | 10001 | 912154267 | 3 | 110000 | ACCRUAL | RESEARCH GRANT |
| MEMORIAL SLOAN-KETTERING CANCER CEN | ||||||||
| 633 THIRD AVENUE | NEW YORK | NY | 10001 | 912154267 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| MEMORIAL SLOAN-KETTERING CANCER CEN | ||||||||
| 633 THIRD AVENUE | NEW YORK | NY | 10001 | 912154267 | 3 | 65000 | ACCRUAL | RESEARCH GRANT |
| MEMORIAL SLOAN-KETTERING CANCER CEN | ||||||||
| 633 THIRD AVENUE | NEW YORK | NY | 10001 | 912154267 | 3 | 65000 | ACCRUAL | RESEARCH GRANT |
| MOUNT SINAI SCHOOL OF MEDICINE | ||||||||
| 1079 ONE GUSTAVE L LEVY PLACE | NEW YORK | NY | 10029 | 136171197 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| MOUNT SINAI SCHOOL OF MEDICINE | ||||||||
| 1130 ONE GUSTAVE L LEVY PLACE | NEW YORK | NY | 10029 | 136171197 | 3 | 110000 | ACCRUAL | RESEARCH GRANT |
| MPN RESEARCH FOUNDATION | ||||||||
| 180 N MICHIGAN AVENUE | CHICAGO | IL | 60601 | 364330967 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| NEW YORK UNIVERSITY SCHOOL OF MEDIC | ||||||||
| 550 FIRST AVENUE | NEW YORK | NY | 10001 | 136171197 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| NEW YORK UNIVERSITY SCHOOL OF MEDIC | ||||||||
| 550 FIRST AVENUE | NEW YORK | NY | 10001 | 136171197 | 3 | 65000 | ACCRUAL | RESEARCH GRANT |
| NEW YORK UNIVERSITY SCHOOL OF MEDIC | ||||||||
| 550 FIRST AVENUE | NEW YORK | NY | 10001 | 136171197 | 3 | 65000 | ACCRUAL | RESEARCH GRANT |
| NEW YORK UNIVERSITY SCHOOL OF MEDIC | ||||||||
| 550 FIRST AVENUE | NEW YORK | NY | 10001 | 136171197 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| NEW YORK UNIVERSITY SCHOOL OF MEDIC | ||||||||
| 550 FIRST AVENUE | NEW YORK | NY | 10001 | 136171197 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| NEW YORK UNIVERSITY SCHOOL OF MEDIC | ||||||||
| 550 FIRST AVENUE | NEW YORK | NY | 10001 | 136171197 | 3 | 65000 | ACCRUAL | RESEARCH GRANT |
| NEW YORK UNIVERSITY SCHOOL OF MEDIC | ||||||||
| 550 FIRST AVENUE | NEW YORK | NY | 10001 | 136171197 | 3 | 110000 | ACCRUAL | RESEARCH GRANT |
| NORTHWESTERN UNIVERSITY - CHICAGO C | ||||||||
| 303 EAST SUPERIOR STREET | CHICAGO | IL | 60601 | 362656113 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| NORTHWESTERN UNIVERSITY - CHICAGO C | ||||||||
| 303 EAST SUPERIOR STREET | CHICAGO | IL | 60601 | 362656113 | 3 | 55000 | ACCRUAL | RESEARCH GRANT |
| NORTHWESTERN UNIVERSITY - CHICAGO C | ||||||||
| 303 E SUPERIOR STREET | CHICAGO | IL | 60611 | 362656113 | 3 | 1250000 | ACCRUAL | RESEARCH GRANT |
| OREGON HEALTH & SCIENCE UNIVERSITY | ||||||||
| 3181 SW SAM JACKSON PARK RD | PORTLAND | OR | 97239 | 237083114 | 3 | 1250000 | ACCRUAL | RESEARCH GRANT |
| OREGON HEALTH & SCIENCE UNIVERSITY | ||||||||
| 3181 SW SAM JACKSON PARK RD | PORTLAND | OR | 97239 | 237083114 | 3 | 110000 | ACCRUAL | RESEARCH GRANT |
| SAINT LOUIS UNIVERSITY | ||||||||
| 1402 SOUTH GRAND AVE | SAINT LOUIS | MO | 63104 | 430654872 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| SLOAN-KETTERING INSTITUTE FOR CANCE | ||||||||
| 1275 YORK AVENUE | NEW YORK | NY | 10065 | 131924236 | 3 | 1250000 | ACCRUAL | RESEARCH GRANT |
| SLOAN-KETTERING INSTITUTE FOR CANCE | ||||||||
| 1275 YORK AVENUE | NEW YORK | NY | 10021 | 131924236 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| SLOAN-KETTERING INSTITUTE FOR CANCE | ||||||||
| 1275 YORK AVENUE | NEW YORK | NY | 10065 | 131924236 | 3 | 55000 | ACCRUAL | RESEARCH GRANT |
| STANFORD UNIVERSITY | ||||||||
| 9500 GILMAN DRIVE | LA JOLLA | CA | 92037 | 237121131 | 3 | 65000 | ACCRUAL | RESEARCH GRANT |
| STANFORD UNIVERSITY | ||||||||
| 9500 GILMAN DRIVE | LA JOLLA | CA | 92037 | 237121131 | 3 | 110000 | ACCRUAL | RESEARCH GRANT |
| STANFORD UNIVERSITY | ||||||||
| 9500 GILMAN DRIVE | LA JOLLA | CA | 92037 | 237121131 | 3 | 65000 | ACCRUAL | RESEARCH GRANT |
| STANFORD UNIVERSITY | ||||||||
| 9500 GILMAN DRIVE | LA JOLLA | CA | 92037 | 237121131 | 3 | 55000 | ACCRUAL | RESEARCH GRANT |
| STANFORD UNIVERSITY | ||||||||
| 9500 GILMAN DRIVE | LA JOLLA | CA | 92037 | 237121131 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| STANFORD UNIVERSITY | ||||||||
| 9500 GILMAN DRIVE | LA JOLLA | CA | 92037 | 237121131 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| STANFORD UNIVERSITY | ||||||||
| 9500 GILMAN DRIVE | LA JOLLA | CA | 92037 | 237121131 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| STANFORD UNIVERSITY | ||||||||
| 9500 GILMAN DRIVE | LA JOLLA | CA | 92037 | 237121131 | 3 | 1250000 | ACCRUAL | RESEARCH GRANT |
| STANFORD UNIVERSITY | ||||||||
| 9500 GILMAN DRIVE | LA JOLLA | CA | 92037 | 237121131 | 3 | 110000 | ACCRUAL | RESEARCH GRANT |
| STANFORD UNIVERSITY | ||||||||
| 9500 GILMAN DRIVE | LA JOLLA | CA | 92037 | 237121131 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| STANFORD UNIVERSITY | ||||||||
| 9500 GILMAN DRIVE | LA JOLLA | CA | 92037 | 237121131 | 3 | 55000 | ACCRUAL | RESEARCH GRANT |
| STANFORD UNIVERSITY MEDICAL CENTER | ||||||||
| 3901 LICKMILL BLVD | SANTA CLARA | CA | 95054 | 770465765 | 3 | 65000 | ACCRUAL | RESEARCH GRANT |
| STANFORD UNIVERSITY MEDICAL CENTER | ||||||||
| 279 CAMPUS DRIVE | STANFORD | CA | 94305 | 770465765 | 3 | 55000 | ACCRUAL | RESEARCH GRANT |
| STANFORD UNIVERSITY MEDICAL CENTER | ||||||||
| 279 CAMPUS DRIVE | STANFORD | CA | 94305 | 770465765 | 3 | 65000 | ACCRUAL | RESEARCH GRANT |
| THE BOARD OF TRUSTEES OF THE LELAND | ||||||||
| 279 CAMPUS DRIVE WEST | STANFORD | CA | 94305 | 376000511 | 3 | 55000 | ACCRUAL | RESEARCH GRANT |
| THE BOARD OF TRUSTEES OF THE UNIVER | ||||||||
| 900 S ASHLAND AVE | CHICAGO | IL | 60607 | 376000511 | 3 | 110000 | ACCRUAL | RESEARCH GRANT |
| THE CBR INSTITUTE FOR BIOMEDICAL RE | ||||||||
| 1 BLACKFAN CIRCLE | BOSTON | MA | 02115 | 042158520 | 1250000 | ACCRUAL | RESEARCH GRANT | |
| THE CHILDREN'S HOSPITAL OF PHILADEL | ||||||||
| 3615 CIVIC CENTER BLVD | PHILADELPHIA | PA | 19104 | 231352166 | 3 | 110000 | ACCRUAL | RESEARCH GRANT |
| THE OHIO STATE UNIVERSITY | ||||||||
| 320 WEST 10TH AVENUE | COLUMBUS | OH | 43210 | 316401599 | 3 | 65000 | ACCRUAL | RESEARCH GRANT |
| THE OHIO STATE UNIVERSITY | ||||||||
| 320 WEST 10TH AVENUE | COLUMBUS | OH | 43210 | 316401599 | 3 | 55000 | ACCRUAL | RESEARCH GRANT |
| THE OHIO STATE UNIVERSITY | ||||||||
| 320 WEST 10TH AVENUE | COLUMBUS | OH | 43210 | 316401599 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| THE OHIO STATE UNIVERSITY | ||||||||
| 320 WEST 10TH AVENUE | COLUMBUS | OH | 43210 | 316401599 | 3 | 1250000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 731 STANLEY HALL MS 3220 | BERKELEY | CA | 94720 | 946002123 | 3 | 55000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 731 STANLEY HALL MS 3220 | BERKELEY | CA | 94720 | 946002123 | 3 | 55000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 731 STANLEY HALL MS 3220 | BERKELEY | CA | 94720 | 946002123 | 3 | 65000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 2150 SHATTUCK AVENUE SUITE 313 | BERKELEY | CA | 94704 | 946002123 | 3 | 55000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 11000 KINROSS AVENUE SUITE 102 | LOS ANGELES | CA | 90095 | 956006143 | 3 | 65000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 9500 GILMAN DRIVE | LOS ANGELES | CA | 90095 | 956006143 | 3 | 110000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 9500 GILMAN DRIVE | LOS ANGELES | CA | 90095 | 956006143 | 3 | 55000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 9500 GILMAN DRIVE | LA JOLLA | CA | 92093 | 952872494 | 3 | 110000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 9500 GILMAN DRIVE | LA JOLLA | CA | 92093 | 952872494 | 3 | 55000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 9500 GILMAN DRIVE | LA JOLLA | CA | 92093 | 952872494 | 3 | 55000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 9500 GILMAN DRIVE | LA JOLLA | CA | 92093 | 952872494 | 3 | 110000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 9500 GILMAN DRIVE | LA JOLLA | CA | 92093 | 952872494 | 3 | 110000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 505 PARNASSUS AVENUESUITE M1286 BO | SAN FRANCISCO | CA | 94143 | 946036493 | 3 | 65000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 505 PARNASSUS AVENUESUITE M1286 BO | SAN FRANCISCO | CA | 94143 | 946036493 | 3 | 55000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 505 PARNASSUS AVENUESUITE M1286 BO | SAN FRANCISCO | CA | 94143 | 946036493 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 505 PARNASSUS AVENUESUITE M1286 BO | SAN FRANCISCO | CA | 94143 | 946036493 | 3 | 110000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 505 PARNASSUS AVENUESUITE M1286 BO | SAN FRANCISCO | CA | 94143 | 946036493 | 3 | 110000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 505 PARNASSUS AVENUESUITE M1286 BO | SAN FRANCISCO | CA | 94143 | 946036493 | 3 | 110000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 505 PARNASSUS AVENUESUITE M1286 BO | SAN FRANCISCO | CA | 94143 | 946036493 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 505 PARNASSUS AVENUESUITE M1286 BO | SAN FRANCISCO | CA | 94143 | 946036493 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 505 PARNASSUS AVENUESUITE M1286 BO | SAN FRANCISCO | CA | 94143 | 946036493 | 3 | 65000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 505 PARNASSUS AVENUESUITE M1286 BO | SAN FRANCISCO | CA | 94143 | 946036493 | 3 | 110000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 505 PARNASSUS AVENUESUITE M1286 BO | SAN FRANCISCO | CA | 94143 | 946036493 | 3 | 110000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 505 PARNASSUS AVENUESUITE M1286 BO | SAN FRANCISCO | CA | 94143 | 946036493 | 3 | 55000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 505 PARNASSUS AVENUESUITE M1286 BO | SAN FRANCISCO | CA | 94143 | 946036493 | 3 | 110000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 505 PARNASSUS AVENUESUITE M1286 BO | SAN FRANCISCO | CA | 94143 | 946036493 | 3 | 55000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 505 PARNASSUS AVENUESUITE M1286 BO | SAN FRANCISCO | CA | 94143 | 946036493 | 3 | 55000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 505 PARNASSUS AVENUESUITE M1286 BO | SAN FRANCISCO | CA | 94143 | 946036493 | 3 | 110000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF CALIFORNIA AT SAN FRA | ||||||||
| 3333 CALIFORNIA STREET SUITE 315 | SAN FRANCISCO | CA | 94143 | 946036493 | 3 | 55000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF MI | ||||||||
| 1500 E MEDICAL CENTER DRIVE | ANN ARBOR | MI | 48109 | 386006309 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF MI | ||||||||
| 1500 E MEDICAL CENTER DRIVE | ANN ARBOR | MI | 48109 | 386006309 | 3 | 110000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF MI | ||||||||
| 1500 E MEDICAL CENTER DRIVE | ANN ARBOR | MI | 48109 | 386006309 | 3 | 110000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF MI | ||||||||
| 1500 E MEDICAL CENTER DRIVE | ANN ARBOR | MI | 48109 | 386006309 | 3 | 110000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF MI | ||||||||
| 1500 E MEDICAL CENTER DRIVE | ANN ARBOR | MI | 48109 | 386006309 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF MI | ||||||||
| 1500 E MEDICAL CENTER DRIVE | ANN ARBOR | MI | 48109 | 386006309 | 3 | 110000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF MI | ||||||||
| 1500 E MEDICAL CENTER DRIVE | ANN ARBOR | MI | 48109 | 386006309 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF MI | ||||||||
| 1500 E MEDICAL CENTER DRIVE | ANN ARBOR | MI | 48109 | 386006309 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF MI | ||||||||
| 1500 E MEDICAL CENTER DRIVE | ANN ARBOR | MI | 48109 | 386006309 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| THE ROCKEFELLER UNIVERSITY | ||||||||
| 1230 YORK AVENUE BOX 202 | NEW YORK | NY | 10065 | 131624158 | 3 | 55000 | ACCRUAL | RESEARCH GRANT |
| THE ROCKEFELLER UNIVERSITY | ||||||||
| 1230 YORK AVENUE BOX 202 | NEW YORK | NY | 10065 | 131624158 | 3 | 55000 | ACCRUAL | RESEARCH GRANT |
| THE ROCKEFELLER UNIVERSITY | ||||||||
| 1230 YORK AVENUE BOX 202 | NEW YORK | NY | 10065 | 131624158 | 3 | 65000 | ACCRUAL | RESEARCH GRANT |
| THE ROCKEFELLER UNIVERSITY | ||||||||
| 1230 YORK AVENUE BOX 202 | NEW YORK | NY | 10065 | 131624158 | 3 | 110000 | ACCRUAL | RESEARCH GRANT |
| THE SCRIPPS RESEARCH INSTITUTE | ||||||||
| 10550 NORTH TORREY PINES ROAD | LA JOLLA | CA | 92037 | 330435954 | 3 | 110000 | ACCRUAL | RESEARCH GRANT |
| THE SCRIPPS RESEARCH INSTITUTE | ||||||||
| 10550 NORTH TORREY PINES ROAD | LA JOLLA | CA | 92037 | 330435954 | 3 | 110000 | ACCRUAL | RESEARCH GRANT |
| THE UNIVERSITY OF ALABAMA AT BIRMIN | ||||||||
| 720 SOUTH 20TH STREET | BIRMINGHAM | AL | 35294 | 636001138 | 3 | 110000 | ACCRUAL | RESEARCH GRANT |
| THE UNIVERSITY OF CHICAGO | ||||||||
| 900 EAST 57TH STREET | CHICAGO | IL | 60601 | 362177139 | 3 | 110000 | ACCRUAL | RESEARCH GRANT |
| THE UNIVERSITY OF CHICAGO | ||||||||
| 900 EAST 57TH STREET | CHICAGO | IL | 60601 | 362177139 | 3 | 65000 | ACCRUAL | RESEARCH GRANT |
| THE UNIVERSITY OF CHICAGO | ||||||||
| 900 EAST 57TH STREET | CHICAGO | IL | 60601 | 362177139 | 3 | 55000 | ACCRUAL | RESEARCH GRANT |
| THE UNIVERSITY OF CHICAGO | ||||||||
| 900 EAST 57TH STREET | CHICAGO | IL | 60601 | 362177139 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| THE UNIVERSITY OF CHICAGO | ||||||||
| 900 EAST 57TH STREET | CHICAGO | IL | 60601 | 362177139 | 3 | 55000 | ACCRUAL | RESEARCH GRANT |
| TRUSTEES OF DARTMOUTH COLLEGE | ||||||||
| 1 MEDICAL CENTER DRIVE | LEBANON | NH | 03756 | 020222111 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| UMDNJ--ROBERT WOOD JOHNSON MEDICAL | ||||||||
| 335 GEORGE STREET | NEW BRUNSWICK | NJ | 08901 | 221776306 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| UNIV OF TEXAS HEALTH SCIENCE CENTER | ||||||||
| 8230 14960 OMICRON DRIVE | SAN ANTONIO | TX | 78245 | 741717115 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| UNIV OF TEXAS HEALTH SCIENCE CENTER | ||||||||
| 8230 14960 OMICRON DRIVE | SAN ANTONIO | TX | 78245 | 741717115 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF ARKANSAS FOR MEDICAL | ||||||||
| 4301 WEST MARKHAM 7 | LITTLE ROCK | AR | 72205 | 716046242 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF CINCINNATI | ||||||||
| 231 ALBERT SABIN WAY | CINCINNATI | OH | 45202 | 316000989 | 3 | 110000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF COLORADO | ||||||||
| 3415 COLORADO AVE UCB 596 | AURORA | CO | 80045 | 846000555 | 3 | 65000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF COLORADO | ||||||||
| 3415 COLORADO AVE UCB 596 | AURORA | CO | 80045 | 846000555 | 3 | 55000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF COLORADO DENVER | ||||||||
| 3415 COLORADO AVE UCB 596 | AURORA | CO | 80045 | 846000555 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF COLORADO DENVER | ||||||||
| 3415 COLORADO AVE UCB 596 | AURORA | CO | 80045 | 846000555 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF COLORADO AT BOULDER | ||||||||
| 3415 COLORADO AVE UCB 596 | AURORA | CO | 80045 | 846000555 | 3 | 55000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF FLORIDA | ||||||||
| 113001 PO BOX | GAINESVILLE | FL | 32601 | 596002052 | 3 | 110000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF FLORIDA | ||||||||
| 113001 PO BOX | GAINESVILLE | FL | 32601 | 596002052 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF MARYLAND BALTIMORE | ||||||||
| 655 WEST BALTIMORE STREET | BALTIMORE | MD | 21201 | 526002033 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF MARYLAND BALTIMORE | ||||||||
| 655 WEST BALTIMORE STREET | BALTIMORE | MD | 21201 | 526002033 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF MASSACHUSETTS MEDICAL | ||||||||
| 364 PLANTATION STREET | WORCESTER | MA | 01605 | 043167352 | 3 | 55000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF MASSACHUSETTS MEDICAL | ||||||||
| 364 PLANTATION STREET | WORCESTER | MA | 01605 | 043167352 | 3 | 110000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF MICHIGAN | ||||||||
| 1500 E MEDICAL CENTER DRIVE | ANN ARBOR | MI | 48109 | 386006309 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF MINNESOTA - TWIN CITI | ||||||||
| 321 CHURCH STREET SE | MINNEAPOLIS | MN | 55401 | 416007513 | 3 | 110000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF MINNESOTA - TWIN CITI | ||||||||
| 321 CHURCH STREET SE | MINNEAPOLIS | MN | 55401 | 416007513 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF MINNESOTA - TWIN CITI | ||||||||
| 321 CHURCH STREET SE | MINNEAPOLIS | MN | 55401 | 416007513 | 3 | 110000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF NORTH CAROLINA AT CHA | ||||||||
| 450 WEST DRIVE | CHAPEL HILL | NC | 27599 | 566001393 | 3 | 55000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF NORTH CAROLINA HOSPIT | ||||||||
| 450 WEST DRIVE ROOM 22-039 | CHAPEL HILL | NC | 27599 | 566001393 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF PENNSYLVANIA | ||||||||
| 421 CURIE BOULEVARD BRBII/IIIRM 53 | PHILADELPHIA | PA | 19104 | 231352685 | 3 | 65000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF PENNSYLVANIA | ||||||||
| 421 CURIE BOULEVARD BRBII/IIIRM 53 | PHILADELPHIA | PA | 19104 | 231352685 | 3 | 65000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF PENNSYLVANIA | ||||||||
| 421 CURIE BOULEVARD BRBII/IIIRM 53 | PHILADELPHIA | PA | 19104 | 231352685 | 3 | 55000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF PENNSYLVANIA | ||||||||
| 421 CURIE BOULEVARD BRBII/IIIRM 53 | PHILADELPHIA | PA | 19104 | 231352685 | 3 | 55000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF PENNSYLVANIA | ||||||||
| 421 CURIE BOULEVARD BRBII/IIIRM 53 | PHILADELPHIA | PA | 19104 | 231352685 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF PENNSYLVANIA | ||||||||
| 421 CURIE BOULEVARD BRBII/IIIRM 53 | PHILADELPHIA | PA | 19104 | 231352685 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF PENNSYLVANIA | ||||||||
| 421 CURIE BOULEVARD BRBII/IIIRM 53 | PHILADELPHIA | PA | 19104 | 231352685 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF PENNSYLVANIA | ||||||||
| 421 CURIE BOULEVARD BRBII/IIIRM 53 | PHILADELPHIA | PA | 19104 | 231352685 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF PENNSYLVANIA | ||||||||
| 421 CURIE BOULEVARD BRBII/IIIRM 53 | PHILADELPHIA | PA | 19104 | 231352685 | 3 | 1250000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF PENNSYLVANIA | ||||||||
| 421 CURIE BOULEVARD BRBII/IIIRM 53 | PHILADELPHIA | PA | 19104 | 231352685 | 3 | 65000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF PENNSYLVANIA | ||||||||
| 421 CURIE BOULEVARD BRBII/IIIRM 53 | PHILADELPHIA | PA | 19104 | 231352685 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF PENNSYLVANIA | ||||||||
| 421 CURIE BOULEVARD BRBII/IIIRM 53 | PHILADELPHIA | PA | 19104 | 231352685 | 3 | 65000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF PENNSYLVANIA | ||||||||
| 421 CURIE BOULEVARD BRBII/IIIRM 53 | PHILADELPHIA | PA | 19104 | 231352685 | 3 | 65000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF PITTSBURGH | ||||||||
| 5117 CENTER AVE | PITTSBURGH | PA | 15213 | 250965591 | 3 | 110000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF ROCHESTER | ||||||||
| 601 ELMWOOD AVENUE | ROCHESTER | NY | 14603 | 160473209 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF ROCHESTER | ||||||||
| 601 ELMWOOD AVENUE | ROCHESTER | NY | 14603 | 160473209 | 3 | 110000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF ROCHESTER | ||||||||
| 601 ELMWOOD AVENUE | ROCHESTER | NY | 14603 | 160473209 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF ROCHESTER | ||||||||
| 601 ELMWOOD AVENUE | ROCHESTER | NY | 14603 | 160473209 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF TEXAS MD ANDERSON C | ||||||||
| 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030 | 760300816 | 3 | 110000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF TEXAS MD ANDERSON C | ||||||||
| 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030 | 760300816 | 3 | 110000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF TEXAS MD ANDERSON C | ||||||||
| 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030 | 760300816 | 3 | 110000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF TEXAS MD ANDERSON C | ||||||||
| 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030 | 760300816 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF TEXAS MD ANDERSON C | ||||||||
| 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030 | 760300816 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF TEXAS MD ANDERSON C | ||||||||
| 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030 | 760300816 | 3 | 110000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF TEXAS MD ANDERSON C | ||||||||
| 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030 | 760300816 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF TEXAS MD ANDERSON C | ||||||||
| 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030 | 760300816 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF TEXAS MD ANDERSON C | ||||||||
| 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030 | 760300816 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF TEXAS MD ANDERSON C | ||||||||
| 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030 | 760300816 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF TEXAS SOUTHWESTERN ME | ||||||||
| 5323 HARRY HINES BOULEVARD | DALLAS | TX | 75390 | 756002868 | 3 | 55000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF UTAH | ||||||||
| 2000 CIRCLE OF HOPE | SALT LAKE CITY | UT | 84112 | 876000525 | 3 | 110000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF UTAH | ||||||||
| 2000 CIRCLE OF HOPE | SALT LAKE CITY | UT | 84112 | 876000525 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF UTAH | ||||||||
| 2000 CIRCLE OF HOPE | SALT LAKE CITY | UT | 84112 | 876000525 | 3 | 55000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF UTAH | ||||||||
| 2000 CIRCLE OF HOPE | SALT LAKE CITY | UT | 84112 | 876000525 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF UTAH | ||||||||
| 2000 CIRCLE OF HOPE | SALT LAKE CITY | UT | 84112 | 876000525 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF UTAH | ||||||||
| 2000 CIRCLE OF HOPE | SALT LAKE CITY | UT | 84112 | 876000525 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF UTAH | ||||||||
| 2000 CIRCLE OF HOPE | SALT LAKE CITY | UT | 84112 | 876000525 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF VERMONT | ||||||||
| 149 BEAUMONT AVE | BURLINGTON | VT | 05405 | 030179440 | 3 | 65000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF WASHINGTON | ||||||||
| 1100 NE 45TH STREET | SEATTLE | WA | 98105 | 916001537 | 3 | 110000 | ACCRUAL | RESEARCH GRANT |
| UT SOUTHWESTERN MEDICAL CENTER | ||||||||
| 5323 HARRY HINES BLVD | DALLAS | TX | 75390 | 760300816 | 3 | 110000 | ACCRUAL | RESEARCH GRANT |
| UT SOUTHWESTERN MEDICAL CENTER | ||||||||
| 5323 HARRY HINES BLVD | DALLAS | TX | 75390 | 760300816 | 3 | 55000 | ACCRUAL | RESEARCH GRANT |
| VIRGINIA COMMONWEALTH UNIVERSITY | ||||||||
| 401 COLLEGE STREET | RICHMOND | VA | 23298 | 546001758 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| WASHINGTON UNIVERSITY IN ST LOUIS | ||||||||
| 660 SOUTH EUCLID AVE | SAINT LOUIS | MO | 63110 | 430653611 | 3 | 200000 | ACCRUAL | RESEARCH GRANT |
| WASHINGTON UNIVERSITY SCHOOL OF MED | ||||||||
| 660 SOUTH EUCLID AVE | SAINT LOUIS | MO | 63110 | 916001537 | 3 | 110000 | ACCRUAL | RESEARCH GRANT |
| WHITEHEAD INSTITUTE FOR BIOMEDICAL | ||||||||
| 9 CAMBRIDGE CENTER | CAMBRIDGE | MA | 02138 | 061043412 | 3 | 110000 | ACCRUAL | RESEARCH GRANT |
| WHITEHEAD INSTITUTE FOR BIOMEDICAL | ||||||||
| 9 CAMBRIDGE CENTER | CAMBRIDGE | MA | 02138 | 061043412 | 3 | 65000 | ACCRUAL | RESEARCH GRANT |
| YALE UNIVERSITY | ||||||||
| 208250 PO BOX | NEW HAVEN | CT | 06510 | 060646973 | 3 | 55000 | ACCRUAL | RESEARCH GRANT |
| YALE UNIVERSITY | ||||||||
| 208250 PO BOX | NEW HAVEN | CT | 06510 | 060646973 | 3 | 55000 | ACCRUAL | RESEARCH GRANT |
| YALE UNIVERSITY | ||||||||
| 208250 PO BOX | NEW HAVEN | CT | 06510 | 060646973 | 3 | 55000 | ACCRUAL | RESEARCH GRANT |
| YALE UNIVERSITY | ||||||||
| 208250 PO BOX | NEW HAVEN | CT | 06510 | 060646973 | 3 | 55000 | ACCRUAL | RESEARCH GRANT |
| SHAPE | ||||||||
| 55 CAMBRIDGE PARKWAY | CAMBRIDGE | MA | 02142 | 263714475 | 3600000 | FMV | THERAPY ACCELERATION | |
| MEMORIAL SLAON KETTERING | ||||||||
| 633 THIRD AVENUE | NEW YORK | NY | 10017 | 912154267 | 3 | 1956100 | FMV | THERAPY ACCELERATION |
| CELATOR PHARMACEUTICALS | ||||||||
| 303B COLLEGE ROAD EAST | PRINCETON | NJ | 08540 | 202680869 | 1888218 | FMV | THERAPY ACCELERATION | |
| EPIZYME INC | ||||||||
| 325 VASSAR STREET | CAMBRIDGE | MA | 02139 | 261349956 | 1500000 | FMV | THERAPY ACCELERATION | |
| ACETYLON PHARMACEUTICALS | ||||||||
| 70 FARGO STREET | BOSTON | MA | 02210 | 263506788 | 1340000 | FMV | THERAPY ACCELERATION | |
| AVILA | ||||||||
| 100 BEAVER STREET | WALTHAM | MA | 02453 | 204599701 | 517483 | FMV | THERAPY ACCELERATION | |
| BECKLOFF ASSOCIATES INC | ||||||||
| 3203 SOLUTIONS CENTER | CHICAGO | IL | 60677 | 480842223 | 525686 | FMV | THERAPY ACCELERATION | |
| CHARLES RIVER LABS | ||||||||
| 251 BALLARDVALLE STREET | WILMINGTON | MA | 01887 | 430918770 | 509300 | FMV | THERAPY ACCELERATION | |
| JOHN HOPKINS UNIVERSITY | ||||||||
| 4545 NORTH CHARLES STREET | BALTIMORE | MD | 21210 | 520595110 | 3 | 500000 | FMV | THERAPY ACCELERATION |
| NANOSYN INC | ||||||||
| 3760 MAVEN AVE | MENLO PARK | CA | 94025 | 860909295 | 207346 | FMV | THERAPY ACCELERATION | |
| FORMA THERAPEUTICS | ||||||||
| 790 MEMORIAL DRIVE | CAMBRIDGE | MA | 02139 | 260428600 | 200000 | FMV | THERAPY ACCELERATION | |
| CELGENE AVILOMIC RESEARCH | ||||||||
| 45 WIGGINS AVENUE | BEDFORD | MA | 01731 | 204599701 | 150000 | FMV | THERAPY ACCELERATION | |
| CLEVELAND CLINIC | ||||||||
| 931568 PO BOX | CLEVELAND | OH | 44193 | 340714585 | 118000 | FMV | THERAPY ACCELERATION | |
| CHILDRENS HOSPITAL OF BOSTON | ||||||||
| 414413 PO BOX | BOSTON | MA | 02241 | 042774441 | 3 | 100000 | FMV | THERAPY ACCELERATION |
| UNIVERSITY OF KANSAS | ||||||||
| 2385 IRVING HILL ROAD | LAWRENCE | KS | 66045 | 480680117 | 3 | 100000 | FMV | THERAPY ACCELERATION |
| THE REGENTS OF THE UNIVERSITY OF MI | ||||||||
| 1500 E MEDICAL CENTER DRIVE | PITTSBURGH | PA | 15251 | 386006309 | 3 | 60372 | FMV | THERAPY ACCELERATION |
| KUMC OUTPATIENT PHARMACY | ||||||||
| 3901 RAINBOW BLVD | KANSAS CITY | KS | 66160 | 481202402 | 58160 | FMV | THERAPY ACCELERATION | |
| ABC LABORATORIES INC | ||||||||
| 4780 DISCOVERY DRIVE | COLUMBIA | MO | 65201 | 430918770 | 54623 | FMV | THERAPY ACCELERATION | |
| SMITHERS PHARMA SERVICES | ||||||||
| 75711 PO BOX | CLEVELAND | OH | 44101 | 201922115 | 25500 | FMV | THERAPY ACCELERATION | |
| PEPTISYNTHA INC | ||||||||
| 23424 NETWORK PLACE | CHICAGO | IL | 60673 | 760315292 | 10000 | FMV | THERAPY ACCELERATION | |
| AMERICAN PEPTIDE | ||||||||
| 1271 AVENIDA CHELSEA | VISTA | CA | 92081 | 943057367 | 9275 | FMV | THERAPY ACCELERATION | |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Nbr Of501 C3 And Govt Grants | 289 | TotalNbrOf501C3AndGovtGrants |
| Total Nbr Of Other Organizations | 19 | TotalNbrOfOtherOrganizations |
Form990 Schedule I Part III Form990ScheduleIPartIII (6 entries)
| Type Of GrantTypeOfGrant | Number Of RecipientsNumberOfRecipients | Amount Of Cash GrantAmountOfCashGrant |
|---|---|---|
| PATIENT AID | 30572 | 3057200 |
| COPAY ASSISTANCE CML | 461 | 416269 |
| COPAY ASSISTANCE CLL | 1618 | 4759699 |
| COPAY ASSISTANCE LYMPHOMA | 6326 | 20625358 |
| COPAY ASSISTANCE MDS | 1213 | 2160000 |
| COPAY ASSISTANCE MYELOMA | 4353 | 18000000 |
Form990 Schedule I Part IV Form990ScheduleIPartIV
| Field | Value | IRS element (for citing) |
|---|---|---|
| Identifier | PROCEDURES FOR MONITORING THE USE OF GRANT FUNDS INSIDE THE UNITED STATES | Identifier |
| Return Reference | SCHEDULE I, PAGE 1, PART I, LINE 2 | ReturnReference |
| Explanation | FIDUCIARY RESPONSIBILITY AND TRANSPARENCY TO OUR DONORS IS A HIGH PRIORITY. THE LEUKEMIA & LYMPHOMA SOCIETY (LLS) PLACES CONSIDERABLE EMPHASIS ON THE OVERSIGHT OF GRANT SPENDING. TO ACCOMPLISH THIS WE REQUIRE THE SUBMISSION OF ANNUAL FINANCIAL REPORTS FOR EACH OF OUR ACTIVE GRANTS. THE REPORT MUST BE SIGNED BY THE FINANCIAL OFFICER AND/OR THE DESIGNATED OFFICIAL OF THE INSTITUTION HOSTING THE AWARD. AT THE END OF THE GRANT, WE REQUIRE A FINAL FINANCIAL REPORT THAT PROVIDES AN OVERVIEW OF ALL SPENDING THROUGH THE DURATION OF THE AWARD. WE REQUIRE SPECIFIC ACCOUNTING OF SPENDING ON PERSONNEL, CONSULTANTS,EQUIPMENT PURCHASES, SUPPLIES, TRAVEL, PATIENT CARE COSTS, ANIMAL CARE COSTS, AND ANY OTHER EXPENSE A GRANTEE MAY INCUR. WE HAVE SPECIFIC INSTRUCTIONS AND DOLLAR AMOUNT LIMITATIONS SET FOR MANY OF THESE CATEGORIES DEPENDING ON THE AWARD TYPE. FINANCIAL REPORTS ARE REVIEWED FOR NUMERICAL ACCURACY, ADHERENCE TO OUR GUIDELINES, AND FOR THE VERIFICATION OF APPROVAL FROM THE INSTITUTION'S FINANCIAL OFFICER. IF THE GRANTEE DOES NOT SUBMIT AN ANNUAL FINANCIAL REPORT BY THE DUE DATE OUTLINED IN THEIR CONTRACT, FUNDING IS SUSPENDED UNTIL LLS RECEIVES AND APPROVES THE DELINQUENT REPORT. | Explanation |
Schedule J IRS990ScheduleJ
| Field | Value | IRS element (for citing) |
|---|---|---|
| Compensation Committee | X | CompensationCommittee |
| Independent Consultant | X | IndependentConsultant |
| Form990 Of Other Organizations | X | Form990OfOtherOrganizations |
| Compensation Survey | X | CompensationSurvey |
| Board Or Committee Approval | X | BoardOrCommitteeApproval |
| Severance Payment | false | SeverancePayment |
| Supplemental Nonqual Retire Plan | false | SupplementalNonqualRetirePlan |
| Equity Based Comp Arrangement | false | EquityBasedCompArrangement |
| Comp Based On Revenue Of Filing Org | false | CompBasedOnRevenueOfFilingOrg |
| Comp Based On Revenue Related Orgs | false | CompBasedOnRevenueRelatedOrgs |
| Comp Based Net Earnings Filing Org | false | CompBasedNetEarningsFilingOrg |
| Comp Based Net Earnings Relate Orgs | false | CompBasedNetEarningsRelateOrgs |
| Any Non Fixed Payments | true | AnyNonFixedPayments |
| Initial Contract Exception | false | InitialContractException |
Form990 Schedule J Part II Form990ScheduleJPartII (9 entries)
| Base Compensation Filing OrgBaseCompensationFilingOrg | Bonus Filing OrgBonusFilingOrg | Other Compensation Filing OrgOtherCompensationFilingOrg | Deferred Comp Filing OrgDeferredCompFilingOrg | Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrg | Total Compensation Filing OrgTotalCompensationFilingOrg |
|---|---|---|---|---|---|
| JOHN WALTER | |||||
| 516875 | 50000 | 14868 | 30870 | 22298 | 634911 |
| JAMES T NANGLE | |||||
| 217599 | 17194 | 9891 | 23479 | 22069 | 290232 |
| LOUIS DEGENNARO | |||||
| 331768 | 32778 | 17932 | 24500 | 15232 | 422210 |
| NANCY KLEIN | |||||
| 331768 | 26223 | 16507 | 24500 | 22270 | 421268 |
| RICHARD WINNEKER | |||||
| 221375 | 25874 | 22726 | 5428 | 982 | 276385 |
| DAVID TIMKO | |||||
| 230080 | 5827 | 11891 | 23591 | 15066 | 286455 |
| MICHAEL OSSO | |||||
| 207050 | 20375 | 17769 | 21205 | 15026 | 281425 |
| JAY SILVER | |||||
| DEREK RAGHAVAN | |||||
Form990 Schedule J Part III Form990ScheduleJPartIII
| Field | Value | IRS element (for citing) |
|---|---|---|
| Identifier | NON-FIXED PAYMENTS PROVIDED | Identifier |
| Return Reference | SCHEDULE J, PAGE 1, PART I, LINE 7 | ReturnReference |
| Explanation | BONUSES WERE PAID BASED ON THE ACHIEVEMENT OF GROSS REVENUE EXCEEDING BUDGETED GROSS REVENUE,EMPLOYEE INDIVIDUAL PERFORMANCE AND OTHER METRICS. BONUSES WERE CAPPED ACCORDING TO LLS'S POLICY.THESE AMOUNTS ARE REPORTED ON SCHEDULE J PART II,COLUMN(B)(II). | Explanation |
Schedule M IRS990ScheduleM
Securities Publicly Traded SecuritiesPubliclyTraded
| Field | Value | IRS element (for citing) |
|---|---|---|
| Non Cash Checkbox | X | NonCashCheckbox |
| Number Of Contributions | 71 | NumberOfContributions |
| Noncash Contribs Rptd F990 | 803655 | NoncashContribsRptdF990 |
| Method Of Determining Revenues | MARKET VALUE | MethodOfDeterminingRevenues |
Food Inventory FoodInventory
| Field | Value | IRS element (for citing) |
|---|---|---|
| Non Cash Checkbox | X | NonCashCheckbox |
| Number Of Contributions | 53 | NumberOfContributions |
Other Non Cash Contributions Table OtherNonCashContributionsTable (3 entries)
| Non Cash CheckboxNonCashCheckbox | DescriptionDescription | Number Of ContributionsNumberOfContributions |
|---|---|---|
| X | PRINTED ITEMS | 2 |
| X | FUNITURE&EQUIP | 6 |
| X | VARIOUS | 73 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Any Property That Must Be Held | false | AnyPropertyThatMustBeHeld |
| Review Process Unusual NC Gifts | true | ReviewProcessUnusualNCGifts |
| Third Parties Used | true | ThirdPartiesUsed |
Form990 Schedule M Part II Form990ScheduleMPartII (3 entries)
| IdentifierIdentifier | Return ReferenceReturnReference | ExplanationExplanation |
|---|---|---|
| THIRD PARTY USED TO PROCESS NONCASH CONTRIBUTIONS | SCHEDULE M, PAGE 1, PART I, LINE 32B | LLS USES ITS INVESTMENT CUSTODIAN TO LIQUIDATE ANY DONATED SECURITIES. |
| EXPLANATION FOR NOT REPORTING REVENUE | SCHEDULE M, PAGE 1, PART I, LINE 33 | LLS ONLY RECORDS DONATED SECURITIES AS REVENUE. ALL OTHER ITEMS FOR WHICH COLUMN A IS CHECKED ARE NOT RECORDED AS REVENUE OR EXPENSE BECAUSE THEY WOULD NOT HAVE BEEN PURCHASED HAD THEY NOT BEEN DONATED, AND ARE IMMATERIAL IN AMOUNT RELATIVE TO THE STATEMENTS OF LLS. |
| SUPPLEMENTAL INFORMATION | SCHEDULE M, PAGE 2, PART II | PART I, COLUMN (B) LLS IS REPORTING THE NUMBER OF CONTRIBUTIONS FOR EACH OF THE ITEMS IN PART I, NOT THE NUMBER OF INDIVIDUAL ITEMS. |
Schedule O IRS990ScheduleO
General Explanation GeneralExplanation (17 entries)
| IdentifierIdentifier | Return ReferenceReturnReference | ExplanationExplanation |
|---|---|---|
| FIRST ACCOMPLISHMENT DESCRIPTION | FORM 990, PAGE 2, PART III, LINE 4A | TO DATE, LLS HAS INVESTED MORE THAN 875 MILLION IN RESEARCH AIMED AT HELPING ALL BLOOD CANCER PATIENTS LIVE BETTER, LONGER LIVES. WE WILL CONTINUE TO SUPPORT RESEARCH THROUGH OUR INNOVATIVE AND INTEGRATED FUNDING PROGRAMS, UNTIL EVERY PATIENT HAS A SAFE AND EFFECTIVE THERAPY. IN FISCAL YEAR 2012, LLS SUPPORTED RESEARCH IN THE U.S., CANADA AND 7 OTHER COUNTRIES WITH A TOTAL RESEARCH DISBURSEMENT OF APPROXIMATELY 66 MILLION. RESEARCH FUNDING WAS DISTRIBUTED ACROSS ALL BLOOD CANCERS. OUR CRITICAL ROLE LLS PROGRAMS ACCELERATE RELEVANT RESEARCH OUTCOMES BY: - BUILDING A FOCUSED RESEARCH WORK-FORCE: ASSURING THE NEXT ROUND OF BREAKTHROUGHS REQUIRES THAT YOUNG INVESTIGATORS BE ENCOURAGED TO WORK IN BLOOD CANCER RESEARCH FIELDS. - TURNING DISCOVERIES INTO NEW THERAPIES: FUNDAMENTAL NEW FINDINGS CAN BE TRANSLATED INTO SAFE AND EFFECTIVE TREATMENTS THAT CAN ULTIMATELY PROLONG AND ENHANCE PATIENT LIVES. - SUPPORTING SYNERGY: LARGE GRANTS AND CONTRACTS ENABLE SCIENTISTS IN ACADEMIA AND THE PRIVATE-SECTOR TO COLLABORATE, COMBINING RESOURCES AND EXPERTISE TO PRODUCE MORE AND FASTER ADVANCES. - FILLING A VOID: RESEARCH PROJECTS THAT ARE HIGH-RISK AND/OR ADDRESS RARE CANCERS ARE LESS LIKELY TO BE FUNDED BY GOVERNMENT AGENCIES OR FOR-PROFIT COMPANIES, BUT MAY PROVIDE IMPORTANT ADVANCES. - SPEEDING NEW TREATMENTS TO PATIENTS: PARTNERING WITH BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES CAN ADVANCE PROMISING THERAPIES THROUGH CLINICAL TESTING, FASTER. PAST ADVANCES MADE WITH LLS RESEARCH FUNDING GENEROUS DONORS HAVE HELPED LLS SUPPORT RESEARCH THAT HAS ALREADY BENEFITED BLOOD CANCER PATIENTS AND MANY OTHERS. ADVANCES INCLUDE: - MULTI-DRUG THERAPIES THAT ARE MORE EFFECTIVE THAN TREATMENTS WITH SINGLE ANTI-CANCER AGENTS, - BONE MARROW / STEM CELL TRANSPLANTATION AND SUPPORTIVE CARE TREATMENTS FOR PATIENTS WHO RELAPSE DESPITE THE BEST AVAILABLE THERAPY, - TESTS THAT DISTINGUISH SPECIFIC CHARACTERISTICS OF PARTICULAR BLOOD CANCERS FOR ACCURATE DIAGNOSIS OF CANCER SUBTYPES, AND FOR "RISK STRATIFICATION" TO SELECT AN OPTIMAL THERAPY. TARGETED THERAPY RESEARCH DISCOVERING THE MOLECULAR ABNORMALITIES THAT CAUSE PARTICULAR TYPES OF BLOOD CANCER HAS BEEN USEFUL IN DIAGNOSIS AND RISK STRATIFICATION, AND IN NEW "TARGETED DRUG" DEVELOPMENT. LLS-FUNDED INVESTIGATORS HAVE HELPED ADVANCE MOLECULARLY TARGETED TREATMENTS THAT CAN SELECTIVELY KILL BLOOD CANCER CELLS VERSUS NORMAL CELLS. MANY OF THESE NEW TREATMENTS BENEFIT NOT ONLY BLOOD CANCER PATIENTS, BUT ALSO PATIENTS WITH OTHER DISEASES. FOR EXAMPLE: - GLEEVEC IS FDA-APPROVED FOR PATIENTS OF ALL AGES WITH CHRONIC MYELOID LEUKEMIA (CML), AND IS ALSO APPROVED FOR PATIENTS WITH ONE FORM OF ACUTE LYMPHOID LEUKEMIA (ALL), MYELODYSPLASTIC SYNDROMES (MDS), MYELOPROLIFERATIVE DISORDERS AND RARE FORMS OF STOMACH AND SKIN CANCERS. RELATED DRUGS, SPRYCEL AND TASIGNA, ARE APPROVED FOR PATIENTS WHO DO NOT BENEFIT FROM GLEEVEC. ONE OR MORE OF THESE DRUGS ARE ALSO SHOWING PROMISE FOR PATIENTS WITH VARIOUS LYMPHOMAS, ACUTE MYELOID LEUKEMIA (AML), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), AND OTHER CANCERS, INCLUDING BRAIN, BREAST, HEAD-AND-NECK, LUNG, PANCREATIC, AND PROSTATE CANCERS, AND PATIENTS WITH OTHER DISEASES INCLUDING ALZHEIMER'S, ASTHMA AND PULMONARY HYPERTENSION. - RITUXAN WAS THE FIRST FDA-APPROVED, ANTI-CANCER ANTIBODY DRUG, DEVELOPED FOR PATIENTS WITH FORMS OF B-CELL NON-HODGKIN LYMPHOMA (NHL). IT IS NOW ALSO APPROVED FOR CLL PATIENTS AND AS A "MAINTENANCE" THERAPY FOR FOLLICULAR LYMPHOMA PATIENTS, AND SHOWING PROMISE FOR PATIENTS WITH ALL AND AFTER STEM CELL TRANSPLANTATION. IN ADDITION, IT IS APPROVED FOR TREATING PATIENTS WITH SEVERE RHEUMATOID ARTHRITIS AND TWO OTHER TYPES OF AUTOIMMUNE DISEASES. A RELATED ANTIBODY DRUG, ARZERRA, IS APPROVED FOR CLL PATIENTS AND SHOWING WIDER PROMISE. - VELCADE, THALIDOMID AND REVLIMID ARE FDA-APPROVED FOR PATIENTS WITH MYELOMA AND ARE ALSO HELPING SOME PATIENTS WITH HODGKIN LYMPHOMA AND NHL. KRYPOLIS WAS RECENTLY APPROVED FOR MYELOMA PATIENTS FOR WHOM AT LEAST TWO PRIOR THERAPIES WERE INSUFFICIENT. ONE OR MORE OF THESE DRUGS ARE NOW BEING TESTED FOR PATIENTS WITH T-CELL AND B-CELL FORMS OF LYMPHOMA, ACUTE LEUKEMIAS, AS WELL AS AIDS-RELATED KAPOSI SARCOMA AND BRAIN, BREAST, COLORECTAL, HEAD-AND-NECK, KIDNEY, LIVER, LUNG, OVARIAN AND PROSTATE CANCERS, AND ALZHEIMER'S DISEASE. - ISTODAX, ZOLINZA, DACOGEN AND VIDAZA TARGET SMALL CHEMICAL, "EPIGENETIC" CHANGES. THE FIRST TWO DRUGS ARE APPROVED FOR PATIENTS WITH PERIPHERAL T-CELL LYMPHOMAS; THE LATTER DRUGS ARE APPROVED FOR MDS PATIENTS. ONE OR MORE OF THESE DRUGS ARE BEING TESTED FOR PATIENTS WITH ALL, AML, CML, CLL, MYELOMA AND FORMS OF NHL, AFTER STEM CELL TRANSPLANTATION, AND FOR PATIENTS WITH BREAST, BRAIN, KIDNEY, COLORECTAL, HEAD-AND-NECK, LUNG, STOMACH, PROSTATE AND OVARIAN CANCERS, MELANOMA AS WELL AS SICKLE CELL DISEASE AND PERSISTENT HIV INFECTIONS. OTHER ACTIVE RESEARCH DIRECTIONS LLS-FUNDED RESEARCHERS ARE ALSO EXPLORING OTHER AREAS OF RESEARCH THAT HOLD PROMISE FOR PATIENTS: - NOVEL STEM CELL TRANSPLANTATION PROCEDURES: THESE INCLUDE SO-CALLED "MINI" TRANSPLANTS THAT USE LESS TOXIC PRE-TRANSPLANT TREATMENTS AND ENGINEERED DONOR CELLS THAT HELP REDUCE POST-TRANSPLANT COMPLICATIONS, MAKING THESE POTENTIALLY CURATIVE TREATMENTS AVAILABLE TO MORE PATIENTS. - IMMUNOTHERAPIES: INCLUDING ANTIBODIES, VACCINES AND ENGINEERED IMMUNE CELLS, THESE TARGETED THERAPIES HELP A PATIENT'S IMMUNE SYSTEM FIGHT INFECTIONS AND KILL RESIDUAL CANCER CELLS, PROLONGING REMISSIONS, AND PERHAPS ONE DAY REPLACING TOXIC CHEMOTHERAPIES. - DIAGNOSTICS: NEW TECHNOLOGIES MAKE IT POSSIBLE TO CHARACTERIZE THE ABNORMALITIES IN INDIVIDUAL CANCER CASES IN MOLECULAR DETAIL. THIS INFORMATION CAN BE USED TO HELP CHOOSE THE BEST POSSIBLE TREATMENT FOR EACH PATIENT, ESPECIALLY AS MORE TARGETED THERAPIES BECOME AVAILABLE. - QUALITY OF LIFE RESEARCH: THESE STUDIES INCREASE OUR UNDERSTANDING OF HOW SPECIFIC TREATMENTS CAN CAUSE DEBILITATING SIDE-EFFECTS, INCLUDING LATE-EFFECTS, AND WHICH PATIENTS ARE AT RISK FOR DEVELOPING THESE COMPLICATIONS, SO THAT THEY CAN BE BETTER MANAGED OR EVEN PREVENTED. DRIVING RESEARCH TO ADDRESS UNMET MEDICAL NEEDS LLS CONTINUES TO SOLICIT AND SUPPORT RESEARCH FOCUSED ON IMPROVING BLOOD CANCER PATIENTS' QUALITY OF LIFE AFTER TODAY'S CURATIVE THERAPIES. ALSO IN 2012, FOR THE SECOND YEAR, LLS ACTIVELY RECRUITED RESEARCH PROPOSALS IN THREE OTHER UNDERDEVELOPED RESEARCH AREAS IN WHICH PROGRESS IS LIKELY TO IMPROVE OUTCOMES FOR PATIENTS WITH PARTICULARLY URGENT NEEDS. NEW RESEARCH IS FOCUSED ON: - THE MALIGNANT STEM CELL IN AML AND MDS - NON-CUTANEOUS T-CELL LEUKEMIAS AND LYMPHOMAS - HIGH RISK MYELOMA CASES THE THERAPY ACCELERATION PROGRAM THIS STRATEGIC INITIATIVE WAS LAUNCHED IN 2007 TO MOVE NEW TREATMENTS AND DIAGNOSTICS THROUGH PRECLINICAL DEVELOPMENT AND CLINICAL TRIALS, FASTER. USING MILESTONE-DRIVEN CONTRACTS AND WORKING IN CONCERT WITH ACADEMIC INVESTIGATORS, MEDICAL CENTERS AND COMPANIES, LLS IS FURTHER BRIDGING THE GAP BETWEEN DISCOVERY AND HUMAN APPLICATIONS TO INCREASE THE LIKELIHOOD THAT NOVEL, POSSIBLY BREAKTHROUGH, TREATMENTS WILL BE AVAILABLE TO PATIENTS AS SOON AS POSSIBLE. THE PROGRAM INCLUDES: - THE ACADEMIC CONCIERGE DIVISION IDENTIFIES ESPECIALLY PROMISING LLS-FUNDED GRANT PROJECTS AND PROVIDES ADDITIONAL SUPPORT TO ADVANCE SELECTED PROJECTS TO THE PRODUCT STAGE. - THE BIOTECHNOLOGY ACCELERATOR DIVISION PARTNERS LLS WITH COMPANIES TO COMBINE SCIENTIFIC AND FINANCIAL RESOURCES AND ACCELERATE THE DEVELOPMENT OF POTENTIAL BLOOD CANCER THERAPIES THAT OTHERWISE MIGHT NOT BE PRIORITIZED BY THE COMPANY.. - THE CLINICAL TRIALS DIVISION BRINGS CLINICAL TRIALS TO BLOOD CANCER PATIENTS IN THEIR COMMUNITIES, INCLUDING UNDER-REPRESENTED POPULATIONS, AND WITH THE ULTIMATE GOAL OF INCREASING PATIENT ENROLLMENT IN BLOOD CANCER TRIALS. |
| SECOND ACCOMPLISHMENT DESCRIPTION | FORM 990, PAGE 2, PART III, LINE 4B | LLS IS COMMITTED TO PROVIDING THE MOST ACCURATE AND UP-TO-DATE BLOOD CANCER INFORMATION. PROFESSIONAL VOLUNTEER CLINICAL ADVISORS WORK WITH LLS STAFF TO REVIEW ALL OF THE INFORMATION LLS PROVIDES THROUGH HEALTHCARE PROFESSIONAL AND PATIENT EDUCATION PROGRAMS, PUBLICATIONS AND THE LLS WEBSITE. A NUMBER OF RESOURCES ARE AVAILABLE IN SPANISH FOR PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS. LLS PUBLISHES AN ANNUAL COMPILATION OF DATA AVAILABLE FOR BLOOD CANCERS, INCLUDING THE ESTIMATED NUMBERS OF NEW BLOOD CANCER CASES AND DEATHS, THE MOST RECENT STATISTICS AVAILABLE FOR INCIDENCE, MORTALITY AND SURVIVAL; AND CURRENT AND ACCURATE INFORMATION ABOUT SYMPTOMS, RISK FACTORS AND TREATMENT. PUBLICATIONS: AN EXTENSIVE CATALOG OF EDUCATION MATERIALS IS OFFERED FREE-OF-CHARGE TO PATIENTS AND HEALTHCARE PROFESSIONALS. EACH YEAR, LLS DISTRIBUTES BOOKLETS, BROCHURES, FACT SHEETS, EDUCATION PROGRAM TRANSCRIPTS AND DVDS THROUGH THE INFORMATION RESOURCE CENTER AND LLS CHAPTERS. MANY MATERIALS ARE ALSO AVAILABLE TO VIEW AND DOWNLOAD AT WWW.LLS.ORG/RESOURCECENTER. DOWNLOADABLE MATERIALS ARE AVAILABLE IN ENGLISH AND SPANISH. - 1,077,533 PRINTED BOOKLETS, BROCHURES, FACT SHEETS, EDUCATION PROGRAM TRANSCRIPTS AND DVDS DISTRIBUTED IN 2012 FINANCIAL ASSISTANCE IN 2012, A COMBINED 48,018,526 DOLLARS WAS AWARDED TO PATIENTS THROUGH THE LLS PATIENT FINANCIAL AID (3,057,200) AND CO-PAY ASSISTANCE PROGRAMS (45,961,326). PATIENT FINANCIAL AID PROGRAM FOR MORE THAN 46 YEARS, LLS HAS HELPED PATIENTS DEMONSTRATING SIGNIFICANT NEED TO OBTAIN FINANCIAL ASSISTANCE TO COVER A PORTION OF THEIR TREATMENT COSTS. THE LLS PATIENT FINANCIAL AID PROGRAM PROVIDES A LIMITED AMOUNT OF FINANCIAL ASSISTANCE TO HELP PATIENTS WITH SIGNIFICANT FINANCIAL NEED AND WHO ARE UNDER A DOCTOR'S CARE FOR A CONFIRMED BLOOD CANCER DIAGNOSIS. PATIENT FINANCIAL AID FUNDS ARE SUBJECT TO AVAILABILITY. - 30,603 PATIENTS RECEIVED FINANCIAL AID IN 2012 CO-PAY ASSISTANCE PROGRAM THIS CO-PAY ASSISTANCE PROGRAM HELPS PATIENTS WITH MANY KINDS OF BLOOD CANCERS MEET THEIR HEALTH INSURANCE OR MEDICARE PLAN PART B OR D PREMIUMS OR CO-PAYMENT OBLIGATIONS RELATED TO TREATING THEIR CANCER. PATIENTS WITH PRESCRIPTION DRUG COVERAGE, MEDICARE BENEFICIARIES UNDER MEDICARE PART B AND/OR MEDICARE PART D, MEDICARE SUPPLEMENTARY HEALTH INSURANCE OR MEDICARE ADVANTAGE SHOULD CHECK WITH LLS TO SEE IF THEY MEET ELIGIBILITY REQUIREMENTS TO RECEIVE FINANCIAL SUPPORT. CO-PAY ASSISTANCE IS SUBJECT TO FUND AVAILABILITY BY SPECIFIC BLOOD CANCER DIAGNOSIS. FOR MORE INFORMATION CALL, (877) LLS-COPAY (877) 557-2672 OR VISIT WWW.LLS.ORG/COPAY. - 13,971 PATIENTS RECEIVED LLS CO-PAY ASSISTANCE IN 2012 COMMUNITY PROGRAMS EACH LLS CHAPTER OFFICE IS STAFFED WITH A PATIENT SERVICES MANAGER (PSM) WHO OVERSEES SERVICES TO PATIENTS AND THEIR FAMILIES, CAREGIVERS AND HEALTHCARE PROFESSIONALS. PSMS ARE HEALTHCARE PROFESSIONALS, OFTEN WITH A BACKGROUND IN ONCOLOGY NURSING OR SOCIAL WORK. PSMS SERVE AS LIAISONS WITH COMMUNITY AND REGIONAL ONCOLOGY/HEMATOLOGY HEALTHCARE PROFESSIONALS AND TREATMENT CENTERS.COMMUNITY-BASED EDUCATION AND OUTREACH, SUPPORT AND PUBLIC POLICY AND ADVOCACY PROGRAMS ARE AVAILABLE. - 43,282 PATIENT AND CAREGIVER PARTICIPANTS IN 2012 - 11,424 HEALTHCARE PROFESSIONAL PARTICIPANTS IN 2012 PROGRAMS FOR CHILDREN AND YOUNG ADULTS THE TRISH GREENE BACK TO SCHOOL PROGRAM FOR CHILDREN WITH CANCER FOCUSES ON INCREASING COMMUNICATION AMONG HEALTHCARE PROFESSIONALS, PARENTS, PATIENTS AND SCHOOL PERSONNEL TO SUPPORT CHILDREN, ADOLESCENTS AND YOUNG ADULTS LIVING WITH CANCER. PRINTED LITERATURE, VIDEOS AND OTHER MATERIALS TO AID THE PROCESS ARE AVAILABLE IN COMMUNITIES THROUGHOUT THE US AND CANADA VIA LLS CHAPTER OFFICES. THE PROGRAM INCLUDES STAYING CONNECTED: FACILITATING THE LEARNING EXPERIENCE DURING AND AFTER CANCER TREATMENT. THIS EDUCATION PROGRAM FOR SCHOOL PERSONNEL, HEALTHCARE PROFESSIONALS AND PARENTS DESCRIBES PHYSICAL, COGNITIVE AND PSYCHOSOCIAL SHORT-AND LONG-TERM EFFECTS THAT CHILDREN, ADOLESCENTS AND YOUNG ADULTS MAY EXPERIENCE DURING AND AFTER TREATMENT. THE PROGRAM OFFERS GUIDANCE AND NUMEROUS RESOURCES TO HELP CHILDREN, ADOLESCENTS AND YOUNG ADULTS CONTINUE THEIR EDUCATION DURING AND AFTER TREATMENT. - 2,957 SCHOOL PERSONNEL, HEALTHCARE PROFESSIONALS AND PARENTS PARTICIPATED IN THE 81 STAYING CONNECTED PROGRAMS ACROSS THE US AND CANADA IN 2012. FAMILY SUPPORT GROUPS LLS HAS DEVELOPED 419 FAMILY SUPPORT GROUPS AT CHAPTERS THROUGHOUT THE US AND CANADA. LLS ALSO HAS 786 VOLUNTEER SUPPORT GROUP FACILITATORS WITH BACKGROUNDS IN ONCOLOGY NURSING OR SOCIAL WORK. GROUPS ARE GUIDED BY TWO VOLUNTEER ONCOLOGY HEALTH PROFESSIONALS, PROVIDING INFORMATION AND SUPPORT AND ENCOURAGING GREATER COMMUNICATION AMONG PATIENTS, FAMILIES, FRIENDS AND HEALTHCARE PROFESSIONALS. - 12,113 PARTICIPANTS IN FAMILY SUPPORT GROUPS IN 2012 PATTI ROBINSON KAUFMANN FIRST CONNECTION PROGRAM FIRST CONNECTION IS A PROGRAM THAT LINKS NEWLY DIAGNOSED PATIENTS TO A PEER VOLUNTEER WHO HAS EXPERIENCED A SIMILAR DIAGNOSIS. A TRAINED PATIENT-VOLUNTEER CURRENTLY IN REMISSION CONTACTS THE NEW PATIENT TO SHARE INFORMATION AND SUPPORT. THIS PROGRAM IS AVAILABLE THROUGH LLS CHAPTERS. - 6,050 FIRST CONNECTIONS IN 2012 |
| THIRD ACCOMPLISHMENT DESCRIPTION | FORM 990, PAGE 2, PART III, LINE 4C | LLS INFORMATION SPECIALISTS ARE MASTER'S LEVEL ONCOLOGY SOCIAL WORKERS, NURSES AND HEALTH EDUCATORS WHO PROVIDE HELP WITH DISEASE, TREATMENT AND CLINICAL TRIAL INFORMATION AND SUPPORT. LLS INFORMATION SPECIALISTS CONDUCT CLINICAL-TRIAL SEARCHES TO HELP PATIENTS WORK WITH THEIR DOCTORS TO FIND OUT ABOUT SPECIFIC CLINICAL TRIALS. PATIENTS, FAMILIES AND HEALTHCARE PROFESSIONALS MAY SPEAK TO AN INFORMATION SPECIALIST AT (800) 955-4572 MONDAY THROUGH FRIDAY, 9 A.M. TO 6 P.M., ET, EMAIL INFOCENTER@LLS.ORG OR CHAT ONE-ON-ONE VIA THE LLS WEBSITE. THE INFORMATION RESOURCE CENTER OFFERS TRANSLATION SERVICES IN MORE THAN 165 LANGUAGES. - 60,012 INQUIRIES IN 2012 THE LLS WEBSITE THE LLS WEBSITE, WWW.LLS.ORG, FULFILLS A WIDE VARIETY OF EDUCATION AND INFORMATION NEEDS. VISITORS CAN PERSONALIZE THEIR WEB PAGES TO KEEP CURRENT WITH DISEASE-SPECIFIC UPDATES AND COMMUNITY EDUCATION AND SUPPORT ACTIVITIES. THE WEBSITE PROVIDES ACCESS TO LLS PROGRAMS AND SERVICES, INCLUDING CO-PAY ASSISTANCE, PATIENT FINANCIAL AID, THE MOST CURRENT AND ACCURATE INFORMATION AND STATISTICS, WEEKLY FACILITATED ONLINE CHATS, NATIONAL TELEPHONE AND WEB EDUCATION PROGRAMS, PUBLICATIONS IN ENGLISH AND SPANISH, AND CLINICAL-TRIAL SEARCHES VIA AN ONLINE CLINICAL-TRIAL SEARCH SERVICE THAT OFFERS PATIENTS AND CAREGIVERS IMMEDIATE ACCESS TO LISTINGS OF BLOOD CANCER CLINICAL TRIALS. PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS CAN INTERACT WITH LLS AND ONE ANOTHER THROUGH SOCIAL NETWORKING, PODCASTS AND ENEWSLETTERS. NATIONAL TELEPHONE/ WEB EDUCATION PROGRAMS LLS SPONSORS TELEPHONE AND WEB EDUCATION PROGRAMS FOR PATIENTS, CAREGIVERS, SURVIVORS AND HEALTHCARE PROFESSIONALS ABOUT LEUKEMIA, LYMPHOMA, MYELOMA AND MYELODYSPLASTIC SYNDROMES. IN 2012, 10 LLS NATIONAL EDUCATION PROGRAMS FEATURED DISEASE-SPECIFIC UPDATES AND INFORMATION ABOUT TREATMENT OPTIONS FROM WORLD RENOWNED CLINICAL EXPERTS. OPPORTUNITIES ARE PROVIDED TO ASK QUESTIONS OF EXPERTS DURING THESE PROGRAMS. MANY OF THESE PROGRAMS INCLUDE CONTINUING EDUCATION CREDITS FOR NURSES AND SOCIAL WORKERS. LLS ALSO SPONSORS A RANGE OF PROFESSIONAL EDUCATION PROGRAMS. RECENT PROGRAMS EXPLORED COMMUNICATION AMONG PRIMARY CARE PROVIDERS AND HEMATOLOGISTS/ONCOLOGISTS IN MANAGING PATIENTS WITH HEMATOLOGIC CANCER AND NURSING MANAGEMENT OF CHALLENGING SIDE EFFECTS. UPCOMING PROGRAMS ARE POSTED AT WWW.LLS.ORG/PROGRAMS AND ARCHIVES OF PAST PROGRAMS ARE AVAILABLE AT WWW.LLS.ORG/PASTPROGRAMS. PROFESSIONAL EDUCATION PROGRAMS ARE AVAILABLE AT WWW.LLS.ORG/PROFESSIONALED. LLS ALSO OFFERS DISEASE-SPECIFIC WEBCASTS PRESENTED BY WORLD RENOWNED CLINICAL EXPERTS. THESE CAN BE ACCESSED AT WWW.LLS.ORG/WEBCASTS. |
| ALL OTHER ACCOMPLISHMENT DESCRIPTION | FORM 990, PAGE 2, PART III, LINE 4D | D) PROFESSIONAL EDUCATION: LLS SERVES THE EDUCATIONAL NEEDS OF THE MEDICAL AND RESEARCH COMMUNITY THROUGH A NUMBER OF PROFESSIONAL EDUCATION SYMPOSIA OFFERED THROUGHOUT THE YEAR. THE EDUCATIONAL PROGRAM OFFERS VARYING FORMATS TO FACILITATE THE EXCHANGE OF INFORMATION AND IDEAS ON THE NEWEST DEVELOPMENTS IN CANCER RESEARCH AND TREATMENT. |
| FINANCIAL ACCOUNTS IN FOREIGN COUNTRIES | FORM 990, PART V, LINE 4B | CANADA |
| CLASSES OF MEMBERS OR STOCKHOLDERS | FORM 990, PAGE 6, PART VI, LINE 6 | THE MEMBERS OF LLS CONSIST OF ONE ELECTED REPRESENTATIVE FROM EACH CHAPTER. |
| ELECTION OF MEMBERS AND THEIR RIGHTS | FORM 990, PAGE 6, PART VI, LINE 7A | THE BOARD OF REPRESENTATIVES (REPRESENTING THE CHAPTERS) ELECTS THE MEMBERS OF LLS'S GOVERNING BODY, ITS NATIONAL BOARD OF DIRECTORS. |
| DECISIONS SUBJECT TO APPROVAL OF MEMBERS | FORM 990, PAGE 6, PART VI, LINE 7B | SIGNIFICANT DECISIONS AFFECTING THE CHAPTERS REQUIRE AN APPROVING VOTE BY THE CHAPTER DELEGATES. DECISIONS NOT SIGNIFICANTLY AFFECTING THE CHAPTERS DO NOT REQUIRE APPROVAL FROM THE CHAPTER DELEGATES. |
| ORGANIZATION'S PROCESS USED TO REVIEW FORM 990 | FORM 990, PAGE 6, PART VI, LINE 11B | THE FORM 990 WAS PREPARED BY THE LLS FINANCE DEPARTMENT AND WAS REVIEWED BY THE CFO, VICE PRESIDENT OF FINANCE, AND KPMG FOR COMMENT AND SUGGESTED REVISIONS. THE FORM 990 WAS THEN PROVIDED TO THE AUDIT COMMITTEE, WHICH IS A COMMITTEE OF THE BOARD OF DIRECTORS. THE AUDIT COMMITTEE REVIEWED THE 990 AND PROVIDED INPUT PRIOR TO FILING. THE FINAL DRAFT FORM 990 WAS PROVIDED TO THE ENTIRE BOARD OF DIRECTORS PRIOR TO FILING BY POSTING THE FORM ON AN INTRANET WEBSITE. |
| ENFORCEMENT OF CONFLICTS POLICY | FORM 990, PAGE 6, PART VI, LINE 12C | ALL EMPLOYEES, BOARD OF DIRECTORS MEMBERS, BOARD OF REPRESENTATIVES MEMBERS, CHAPTER BOARD MEMBERS, FAMILY SUPPORT GROUP FACILITATORS, AND TNT COACHES ARE REQUIRED TO REVIEW THE CONFLICT OF INTEREST POLICY ON AN ANNUAL BASIS AND SUBMIT A SIGNED FORM ACKNOWLEDGING THAT THEY HAVE REVIEWED THE POLICY AND DISCLOSED ANY CONFLICTS OF INTEREST. ALL FORMS ARE COLLECTED AND THE AUDIT COMMITTEE REVIEWS ANY FORMS DISCLOSING A POSSIBLE CONFLICT OF INTEREST AND DETERMINES WHETHER OR NOT A CONFLICT EXISTS. |
| COMPENSATION PROCESS FOR TOP OFFICIAL | FORM 990, PAGE 6, PART VI, LINE 15A | THE EXECUTIVE COMMITTEE, COMPRISED OF INDEPENDENT MEMBERS OF THE BOARD OF DIRECTORS, REVIEWS AND MONITORS THE CHIEF EXECUTIVE OFFICER'S PERFORMANCE AND COMPENSATION. THE COMMITTEE OBTAINED A SURVEY OF OTHER NOT-FOR-PROFIT ORGANIZATIONS' COMPENSATION RANGES AND SET THE CHIEF EXECUTIVE'S SALARY COMMENSURATELY. THE REVIEW WAS DOCUMENTED IN THE EXECUTIVE COMMITTEE'S MINUTES. |
| COMPENSATION PROCESS FOR OFFICERS | FORM 990, PAGE 6, PART VI, LINE 15B | THE EXECUTIVE COMMITTEE, COMPRISED OF INDEPENDENT MEMBERS OF THE BOARD OF DIRECTORS, REVIEWED A SURVEY OF OTHER NOT-FOR-PROFIT ORGANIZATIONS' COMPENSATION RANGES AND COMPARED THIS TO THE OTHER OFFICER'S SALARY AND DETERMINED THAT IT WAS APPROPRIATE. THE REVIEW WAS DOCUMENTED IN THE EXECUTIVE COMMITTEE'S MINUTES. |
| STATES WHERE COPY OF RETURN IS FILED | FORM 990, PAGE 6, PART VI, LINE 17 | , ALASKA, ALABAMA, ARKANSAS, ARIZONA, CALIFORNIA, COLORADO, CONNECTICUT, DELAWARE, DIST OF COLUMBIA, FLORIDA, GEORGIA, HAWAII, IDAHO, ILLINOIS, INDIANA, KANSAS, KENTUCKY, LOUISIANA, MASSACHUSETTS, MARYLAND, MAINE, MICHIGAN, MINNESOTA, MISSOURI, MISSISSIPPI, NEW HAMPSHIRE, NEW JERSEY, NEW MEXICO, NEBRASKA, NEW YORK, OHIO, OKLAHOMA, OREGON, PENNSYLVANIA, PUERTO RICO, RHODE ISLAND, SOUTH CAROLINA, TENNESSEE, UTAH, VIRGINIA, WASHINGTON, WISCONSIN, WEST VIRGINIA |
| GOVERNING DOCUMENTS DISCLOSURE EXPLANATION | FORM 990, PAGE 6, PART VI, LINE 19 | THE LEUKEMIA & LYMPHOMA SOCIETY, INC. MAKES ITS ANNUAL FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC ON ITS WEBSITE AT WWW.LLS.ORG. ITS GOVERNING DOCUMENTS ARE MADE AVAILABLE, WHEN CHANGES ARE MADE, AS PART OF THE 990 AVAILABLE FOR PUBLIC INSPECTION. ANY IDENTIFIED CONFLICTS OF INTEREST ARE DISCLOSED IN THE 990. |
| RELATED ORGANIZATIONS | FORM 990, PAGE 7, PART VII | JOHN WALTER PRESIDENT & CEO, SCOTT CARROLL BOD CHAIR, TIMOTHY DURST BOD VICECHAIR, AND STEVEN HOOKER BOD SECRETARY/TREASURER SPEND LESS THAN 1 HOUR PER MONTH ON THE BUSINESS OF OUR RELATED ORGANIZATIONS LSRP13-3470494,AND LSRF 13-3709252. THE LARGEST AMOUNT OF TIME THEY SPEND ON LSRF AND LSRP IS DURING THEIR ANNUAL REVIEW OF THE ORGANIZATIONS IRS FORM 990, AND 990EZ FILINGS. |
| OTHER CHANGES IN NET ASSETS EXPLANATION | FORM 990, PART XI, LINE 5 | RECONCILIATION OF CHANGE IN NET ASSETS ON A CONSOLIDATED BASIS TO SEPARATE COMPANY BASIS: CHANGE IN NET ASSETS PER AUDITED FINANCIAL STATEMENTS (6,266,084) PLUS: CHANGE IN NET ASSETS LLS CANADA 439,080 PLUS: LLSRF AND LLSRP ACTIVITY (41,507) PLUS: FOREIGN CURRENCY TRANSLATION ADJUSTMENT 133,400 PLUS: AUDITED FINANCIAL STATEMENT ROUNDING (3) EQUALS: CHANGE IN NET ASSETS PER 990 (5,735,114) SCHEDULE D PART XI LINE 9 (6,694,563) CHANGE IN NET ASSETS ABOVE 530,970 990 PART XI LINE 5 (6,163,593) THE AUDITED FINANCIAL STATEMENTS FOR THE LEUKEMIA & LYMPHOMA SOCIETY, INC. INCLUDE THE LEUKEMIA & LYMPHOMA SOCIETY OF CANADA, THE LEUKEMIA & LYMPHOMA SOCIETY RESEARCH PROGRAMS, INC., AND THE LEUKEMIA & LYMPHOMA SOCIETY RESEARCH FOUNDATION IN ADDITION TO LLS. |
| ADDITIONAL INFORMATION | FORM 990, PART XII | JAY SILVER RESIGNED FROM THE BOD APRIL 20, 2012 DEREK RAGHAVAN RESIGNED FROM THE BOD MARCH 14, 2012 |
Schedule R IRS990ScheduleR
Form990 Schedule R Part II Form990ScheduleRPartII (3 entries)
| Address Line1AddressForeign/AddressLine1 | CityAddressForeign/City | CountryAddressForeign/Country | Postal CodeAddressForeign/PostalCode | Primary ActivitiesPrimaryActivities | Legal Domicile Foreign CountryLegalDomicileForeignCountry | Business Name Line1DirectControllingEntityName/BusinessNameLine1 | Controlled OrgControlledOrg | Address Line1AddressUS/AddressLine1 | CityAddressUS/City | StateAddressUS/State | ZIP CodeAddressUS/ZIPCode | EINEIN | Legal Domicile StateLegalDomicileState | Exempt Code SectionExemptCodeSection | Public Charity StatusPublicCharityStatus |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| THE LLS OF CANADA | |||||||||||||||
| 804 2 LANSING SQUARE | TORONTO | CA | M2J4P8 | PART VII | CA | NA | false | ||||||||
| THE LLS RESEARCH PROGRAMS INC | |||||||||||||||
| PART VII | LLS INC | true | 1311 MAMARONECK AVENUE | WHITE PLAINS | NY | 10605 | 133470494 | DE | 501C3 | 11B | |||||
| THE LLS RESEARCH FOUNDATION | |||||||||||||||
| PART VII | LLS INC | true | 1311 MAMARONECK AVENUE | WHITE PLAINS | NY | 10605 | 133709252 | DE | 501C3 | 11B | |||||
| Field | Value | IRS element (for citing) |
|---|---|---|
| Receipt Of Int Ann Rents Royalties | false | ReceiptOfIntAnnRentsRoyalties |
| Gift Grant Or Cap Contr To Other Org | false | GiftGrantOrCapContrToOtherOrg |
| Gift Grant Or Cap Contr Fr Other Org | true | GiftGrantOrCapContrFrOtherOrg |
| Loans Or Guarantees To Other Org | true | LoansOrGuaranteesToOtherOrg |
| Loans Or Guarantees From Other Org | false | LoansOrGuaranteesFromOtherOrg |
| Sale Of Assets To Other Org | false | SaleOfAssetsToOtherOrg |
| Purchase Of Assets From Other Org | false | PurchaseOfAssetsFromOtherOrg |
| Exchange Of Assets | false | ExchangeOfAssets |
| Rental Of Facilities To Other Orgs | false | RentalOfFacilitiesToOtherOrgs |
| Rental Of Facilities Fr Other Orgs | false | RentalOfFacilitiesFrOtherOrgs |
| Perform Of Services For Other Orgs | false | PerformOfServicesForOtherOrgs |
| Perform Of Services By Other Orgs | false | PerformOfServicesByOtherOrgs |
| Sharing Of Facilities | true | SharingOfFacilities |
| Sharing Of Paid Employees | true | SharingOfPaidEmployees |
| Reimbursement Paid To Other Org | false | ReimbursementPaidToOtherOrg |
| Reimbursement Paid By Other Org | false | ReimbursementPaidByOtherOrg |
| Other Transfer To Other Org | false | OtherTransferToOtherOrg |
| Other Transfer From Other Org | false | OtherTransferFromOtherOrg |
Transactions Related Orgs Table TransactionsRelatedOrgsTable (2 entries)
| Transaction TypeTransactionType | Amount InvolvedAmountInvolved | Method Of Amt DeterminationMethodOfAmtDetermination |
|---|---|---|
| THE LEUKEMIA & LYMPHOMA SOCIETY | ||
| D | 164921 | COST |
| OF CANADA | ||
Form990 Schedule R Part VII Form990ScheduleRPartVII
| Field | Value | IRS element (for citing) |
|---|---|---|
| Identifier | GROUP EXEMPTION RELATIONSHIPS | Identifier |
| Return Reference | SCHEDULE R | ReturnReference |
| Explanation | THE LEUKEMIA LYMPHOMA SOCIETY OF CANADA CARRIES OUT THE SAME PRIMARY ACTIVITIES AS THE LEUKEMIA LYMPHOMA SOCIETY INC IN CANADA THE LEUKEMIA SOCIETY RESEARCH PROGRAMS INC AND THE LEUKEMIA RESEARCH FOUNDATION INC SUPPORT THE ACTIVITIES OF THE LEUKEMIA LYMPHOMA SOCIETY INC | Explanation |